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Abstract 
This study investigated the effects of nicotine on memory and learning in adolescent and 
adult male Fischer-344 rats.  Rats were given 0.2 mg/kg/day of either nicotine or saline 
chronically for 2 weeks and were tested in the Morris water maze as adolescents (Phase 
1) and then again 4 months later as adults (Phase 2).  There were 4 main groups:  
nicotine/nicotine, nicotine/saline, saline/nicotine, and saline/saline.  In Phase 2 rats were 
tested for c-Fos and BrdU expression in the dentate gyrus of the hippocampus.  
Behavioral data indicated that as adults, rats given nicotine were significantly improved 
at the water maze task compared to rats given saline.  Impairments of the S/N group 
suggest performance in the maze is state dependent upon the nicotine.  An increase in c-
Fos expression was seen in the saline rats, and no BrdU expression was seen in either 
group.  The behavioral results imply that low doses of nicotine improve learning and 
memory in adult rats.  This provides support for studies investigating nicotine as a 
therapeutic agent for diseases affecting cognition, such as Alzheimer’s.    
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Just Say “Nootropic”: The Effects of Nicotine on Memory and Learning  
in Adolescent and Adult Rats 
 For the past twenty years, nicotine and drugs that act as agonists to nicotinic 
receptors have been under investigation due to their cognitive enhancing properties and 
their potential for therapeutic use in certain neurodegenerative diseases, schizophrenia, 
and attention deficit hyperactivity disorder (Dunbar et al., 2007; Levin & Rezvani, 2000; 
Rezvani & Levin, 2001; White & Levin, 1999, , 2004).  At the present time, the drugs 
available to patients suffering from Alzheimer’s disease and other diseases affecting 
cognition provide minimal relief of symptoms.  Most of these drugs involve the indirect 
stimulation of cholinergic receptors, however studies have shown that direct stimulation 
of nicotinic receptors—via nicotine itself or nicotinic agonists—may have a more 
pronounced therapeutic effect (Ono, Hasegawa, Yamada, & Naiki, 2002; Rezvani & 
Levin, 2001).  Thus, nicotine research has provided some promising results regarding 
possible therapies for such diseases. 
Nicotine: Neural Mechanisms 
Nicotine, the main psychoactive ingredient found in tobacco, mimics the effects 
of acetylcholine (ACh) at nicotinic ACh receptors (nAChRs).  Like ACh, it modulates the 
signaling pathways of target neurons by stimulating the release of several 
neurotransmitters that are associated with memory, learning, and reward, including 
acetylcholine, glutamate, dopamine, norepinephrine, and serotonin (Fagen, Mansvelder, 
Keath, & McGehee, 2003; Levin, Limpuangthip, Rachakonda, & Peterson, 2006; 
Mansvelder, van Aerde, Couey, & Brussaard, 2006; Rezvani & Levin, 2001; Wang et al., 
2008).  It has been confirmed by multiple studies that nicotine has a pronounced effect on 
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areas of the brain linked with reward, specifically the mesolimbic system, through the 
increased release of dopamine (Clarke, 1992; Di Chiara, Acquas, Tanda, & Cadoni, 
1992).  This is the essence of the controversy surrounding nicotine as a therapeutic drug: 
its stimulation of receptors that release reward-based neurotransmitters could lead to 
addiction, particularly if the dose is high and self-administration is possible (Merlo Pich, 
Chiamulera, & Carboni, 1999; Wang et al., 2008).   
Despite this controversy, addiction studies of nicotine provide some important 
information that leaves the door open for nicotine’s use in diseases affecting cognition.  
The most common way people become addicted to nicotine is via cigarette smoking 
(Winger, Woods, & Hofmann, 2004).  However, when nicotine is introduced into the 
body in this way, a large amount of nicotine reaches the brain extremely rapidly on 
inhalation.  The immediate, semi-euphoric effect that results is what increases the 
likelihood for nicotine addiction (Winger et al., 2004).  Additionally, studies involving 
self-administration of nicotine in rats have shown that when rats are allowed to self-
administer, they take in doses of nicotine on par with that of a cigarette smoker, which 
contributes to research labeling it as addictive (Abrous et al., 2002).  Evidence suggests 
that when nicotine is administered to animals (or humans) at a slow rate and in a 
controlled manner (not through cigarettes or tobacco), the possibility for addiction is 
much lower (Samaha, Yau, Yang, & Robinson, 2005).  Thus, as long as the dose of 
nicotine is low and patients are on a well-defined schedule, it is less likely to produce an 
addiction and has the potential to be a safe therapeutic alternative.   
Though nicotine is the main rewarding component in cigarettes and the reason 
smoking can be addictive, it is important to understand that the harmful effects of 
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smoking are largely due to the combination of an estimated 4000 constituents of cigarette 
smoke—not the nicotine itself (Winger et al., 2004).  When the smoke turns to vapor it 
has high amounts of toxic carbon monoxide, which adds to the harmful effects of 
cigarette smoking (Winger et al., 2004).  Because of the toxic nature of the ingredients in 
cigarettes and their reactions to being burned, it is no surprise that cigarette smoking can 
lead to serious illnesses such as coronary heart disease, emphysema and various forms of 
cancer (Winger et al., 2004).  Nicotine alone, especially when administered intravenously 
or by transdermal patches, does not cause these health problems (Winger et al., 2004).   
 The action of nicotine in the brain relies upon nAChRs.  These receptors are 
ligand-gated ion channels containing five subunits that form a circle around a central 
pore, and allow the influx of positively charged ions.  Subunits can be either alpha, beta, 
gamma, or delta, but the subunits most connected to nicotinic involvement are alpha 4 
beta 2 (α4β2) subunits or alpha 7 (α7) subunits (Hawi & Lowe, 2007; Winger et al., 
2004).  When a nicotine molecule binds to a receptor, the receptor opens and allows 
positively charged ions to enter.  This leads to an excitatory postsynaptic potential 
(EPSP), which increases the likelihood of neurotransmitter release from the responding 
cell.  It is this potential for neurotransmitter release that leads to nicotine’s cognitive 
enhancing effects.  The makeup of the subunits of the receptor as well as the location of 
the receptor in the brain dictates the effect of the neurotransmitter release within the brain 
(Winger et al., 2004).   
Mouse studies of nicotine’s effect on gene expression and receptors have reported 
that nicotine administration results in receptor upregulation in the nucleus accumbens 
(one area from which nicotine is known to stimulate the release of dopamine), as well as 
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in the hippocampus, which is highly involved in learning and memory (Wang et al., 
2008).  Receptor upregulation is an increase in available receptors in the brain that can 
occur in response to a large amount of drug present in that brain area.  In order to provide 
a place for the extra drug molecules to bind, receptors multiply—this results in an 
increased effect of the drug, and also leads to the potential for withdrawal symptoms if 
the drug is suddenly ceased.  When receptors are exposed to a large amount a drug, 
however, receptors can become desensitized and receptor downregulation can occur as a 
compensatory mechanism (Benwell, Balfour, & Birrell, 1995).   
With regard to nicotine’s action upon certain receptors, much promising data has 
come from studies concerning nicotinic cholinergic receptors in rats and mice.  The α7 
and α4β2 receptors, in particular, have been demonstrated to play a role in cognitive 
functioning (Levin, McClernon, & Rezvani, 2006).  A study using α7- nAChR knockout 
mice determined that mice missing these receptors performed poorly on attentional tasks 
of cognitive function when compared to normal controls (Young et al., 2007).  
Experiments performed with rats in a passive avoidance test also demonstrated that both 
chronic and acute nicotine administration had cognitive-enhancing effects as a result of 
α7-nAChR stimulation in the hippocampus (Uzum, Diler, Bahcekapili, Tasyurekli, & 
Ziylan, 2004).  Wild-type mice with α7-nAChRs have also demonstrated more cell 
proliferation as a result of nicotine administration when compared to mice lacking these 
receptors (Koike et al., 2004). 
The Hippocampus  
 Multiple studies have shown that nicotine has a positive effect on memory and 
learning in humans and non-human animals, and one of the areas of the brain most 
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affected by nicotine administration is the hippocampus (Levin, Sledge, Baruah, & Addy, 
2003; Wang et al., 2008).  The hippocampus plays a key role in learning and memory, 
particularly learning and memory involving spatial information (Izquierdo, 1995).  Long 
Term Potentiation (LTP) is the mechanism that allows for the hippocampus’ involvement 
in memory storage and memory retrieval (Izquierdo, 1995).  LTP is an increase in 
synaptic effectiveness, which can result in changes in the synapses, an increase in 
synaptic firing and an increase in neurotransmission in the hippocampus (Schumann et 
al., 2004).  Spatial learning tasks such as the Morris water maze can increase LTP in the 
rat hippocampus, and it is possible that nicotine can also facilitate this process in 
conjunction with these tasks.   
 One group has proposed that glutamate release in the hippocampus is enhanced by 
nicotine.  They examined the effect of nicotine and a glutamate agonist (dizocilpine) on 
spatial learning in the radial arm maze.  When the rats were given dizocilpine in 
conjunction with nicotine, they displayed an impairment in working memory in the maze 
(Levin et al., 2003).  The dizocilpine was administered via a local infusion cannula in the 
ventral hippocampus, so the impairment in working memory was localized specifically to 
this brain area (Levin et al., 2003).  This result provides support for the notion that the 
hippocampus is an integral brain area in the formation of working memory, and that 
glutamate neurotransmission as a result of nicotine administration is central to the 
cognitive enhancing properties of nicotine. 
Cognitive Enhancement in Humans 
 There have been numerous studies investigating nicotine’s effect on human 
cognition.  It has been shown that when regular smokers are deprived of cigarettes they 
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experience withdrawal symptoms that include cognitive deficits, such as decreased 
accuracy on tasks of performance, and a decrease in psychomotor skills (Hatsukami, 
Fletcher, Morgan, Keenan, & Amble, 1989).  One study demonstrated that as little as 24 
hours after cigarette cessation, reaction times and errors related to vigilance tasks were 
significantly increased (Hatsukami et al., 1989).  Though it is possible that the cognitive 
decline could have been due in part to the other symptoms of withdrawal from cigarettes 
(including headaches, nausea, etc.), it is likely that the decline was at least partially a 
result of the cessation of nicotine.  In 24 hours the participants in the study were not 
reported to have any other noticeable withdrawal symptoms, which supports the notion 
that the removal of nicotine was a contributing factor to the decrease in performance on 
the cognitive tasks.   
Due to the potential for cognitive decline following nicotine cessation in cigarette 
smokers, it is beneficial to investigate the effect of nicotine on adult non-smokers without 
any attentional or cognitive deficits—this research demonstrates nicotine’s effectiveness 
in improving cognition in normal, healthy controls.  Non-smokers are an ideal baseline in 
these types of studies because there is no possibility of withdrawal, which could skew the 
results.  Additionally, regular smokers would have to change their smoking patterns for 
the study, which would introduce even more potential for variation in the results 
(Hatsukami et al., 1989; Levin & Rezvani, 2000; Rezvani & Levin, 2001).  Nicotine has 
been shown to improve the attention of non-smoking normal controls when administered 
through subcutaneous injections and transdermal nicotine patches, suggesting that it may 
also have a similar effect on patients with attentional disorders or other cognitive 
impairments (Levin, Conners et al., 1998; Levin & Rezvani, 2000). 
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Alzheimer’s Disease 
Because nicotine enhances the cognition of human non-smokers, it has been of 
great interest to researchers whether it could have cognitive enhancing—and therefore 
therapeutic—effects on people with various cognitive ailments, including Alzheimer’s 
disease.  Alzheimer’s disease (AD) is characterized by severe cognitive deficits, 
including impairments of memory and executive (higher-order) function (Nixon, 2002).  
Generally these deficits begin mildly, and become progressively worse as increased cell 
death leads to severe cortical atrophy (Nixon, 2002).  The most widely understood 
neuropathology of post-mortem Alzheimer’s brains includes the presence of 
neurofribrillary tangles and neuritic plaques (Buckner, Head, & Lustig, 2006; Nixon, 
2002).  The neuritic plaques are found largely in brain areas involved in learning and 
memory, such as the neocortex, the hippocampus, and the amygdala.  This provides 
insight into Alzheimer’s negative effect on cognition as the disease progresses (Nixon, 
2002).   
In 2002, Ono and colleagues demonstrated that nicotine interferes with the 
formation of in vitro amyloid plaques.  This provides important information regarding the 
neuroprotective effects of nicotine that extend beyond nicotinic receptor upregulation, 
and supports the notion that nicotine can be used as a therapeutic agent in Alzheimer’s 
disease.  Studies have also shown that the neuropathology of postmortem Alzheimer’s 
brains involves a significant decrease in nAChRs compared to that of normal ageing 
(Court et al., 2001).  Because nicotine administration results in an upregulation of 
nAChRs, this effect could help delay some of the more severe cognitive deficits of the 
disease by keeping the nAChR level in the brain stable and increasing neurotransmission. 
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Studies of nicotine’s effects in humans are generally carried out using injections, 
nasal sprays, or transdermal nicotine patches.  These methods of nicotine administration 
cause nicotine to reach the brain much more slowly and are less likely to lead to a 
nicotine addiction than smoking, in which nicotine reaches the brain extremely rapidly 
(Samaha et al., 2005).  The first study investigating the effects of intravenous nicotine 
administration on Alzheimer’s patients used extremely small doses of nicotine, and found 
that even when the dose was as small as 0.25 μg/kg/min, AD patients showed decreased 
errors on a test of cognitive function (Newhouse et al., 1988).  In studies using acute 
nicotine doses of 0.4 to 0.8 mg, significant cognitive enhancement was demonstrated in 
normal controls as well as Alzheimer’s patients on various tests of attention and cognitive 
function (Jones, Sahakian, Levy, Warburton, & Gray, 1992; Sahakian, Jones, Levy, Gray, 
& Warburton, 1989).  More recently, however, the transdermal nicotine patch has been 
used in order to provide a larger dose and to avoid the necessity of injections.  In a pilot 
study demonstrating the effects of the nicotine patch in AD patients, Wilson and 
colleagues (1995) demonstrated that the nicotine group (still receiving a moderate dose—
0.9 mg/hr) showed improved learning.  This was a result that had not been previously 
reported (early studies only showed improved attention), and it paved the way for further 
research in this area (Wilson et al., 1995).   
In 1999, White and Levin investigated the effect of a 5 mg transdermal nicotine 
patch when worn by patients with mild to moderate Alzheimer’s disease, and found that 
the nicotine significantly improved patients’ performance on a task of attention, but there 
were no significant differences relating to motor or memory function (White & Levin, 
1999).  Later, White and Levin (2004) performed a similar study using 5 mg transdermal 
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nicotine patches on patients with age-associated memory impairment (AAMI), which has 
milder cognitive deficits than AD.  Using the same scale as in the previous study (the 
Conners’ Continuous Performance Test), they were able to demonstrate the same increase 
in attention as a result of the nicotine administration in AAMI patients (White & Levin, 
2004).  Though in White and Levin’s studies no significant effects were seen in memory, 
studies using nicotinic receptor agonists that report an improvement in declarative 
memory, as well as the Wilson et al. (1995) study that showed improved learning, 
provide evidence that nicotine can help alleviate the memory deficits found in AD and 
other diseases affecting cognition (Potter et al., 1999).   
Parkinson’s Disease 
 In addition to nicotine’s positive effect on patients suffering from diseases that 
primarily affect cognition, nicotine has also been shown to be therapeutic in Parkinson’s 
disease (PD), a neurodegenerative disease characterized by impairments in motor 
coordination and function (Quik, 2004).  The neuropathology of PD involves damage to 
dopaminergic nigrostriatal neurons.  This leads to the motor deficits of the disease, which 
include tremor, rigidity, akinesia, bradykinesia, and gait disturbances (Mazziotta, Toga, 
& Frackowiak, 2000; Quik, 2004).   Though not as prevalent as the motor symptoms, 
patients with Parkinson’s disease can also suffer from dementia, which is one of the 
reasons nicotine has been investigated as a potential therapeutic agent (Quik, 2004).  This 
branch of research was first investigated after a series of studies emerged suggesting that 
Parkinson’s disease is less prevalent in cigarette smokers, and that smoking can 
potentially delay the onset of the disease (Fujita et al., 2006; Quik, 2004).  It was thought 
that the nicotine in cigarettes played a key role in this delay due to its stimulation of 
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dopaminergic nigrostriatal neurons, and its neuroprotective effects (Quik, 2004).   In 
addition to this, a neuroimaging study comparing nAChR expression in normal controls 
vs. Parkinson’s patients concluded that patients with PD display a significant decrease in 
nAChRs, and that nicotine could be beneficial to these patients as well as patients with 
other neurodegenerative disease because it stimulates these receptors (Fujita et al., 2006).   
 A longitudinal study investigating the effects of high-dose nicotine administered 
via transdermal patches on Parkinson’s patients confirmed the hypothesis that nicotine 
can be beneficial to such patients (Villafane et al., 2007).  Patients were given increasing 
daily doses of nicotine (5-105 mg/day) for 14 weeks, keeping the highest tolerated dose 
constant for at least 4 weeks before gradually decreasing the dose until the conclusion of 
the experiment at week 29.  Though most patients experienced symptoms of nausea and 
insomnia, all patients demonstrated improved motor ability and required less of their 
usually prescribed dopaminergic drugs by the end of the study (Villafane et al., 2007).  
The ideal daily dose was determined to be between 45 and 90 mg/day, and because this 
study was done over such a long duration, it provides convincing findings regarding 
nicotine’s potential as a therapeutic agent for the motor symptoms of Parkinson’s disease 
(Villafane et al., 2007).   
Schizophrenia 
Schizophrenia, a type of recurring psychosis that can have detrimental effects on 
cognition, emotion, perceptions, and even motor function, is another illness that has long 
been known to have a therapeutic tie to nicotine (Kraly, 2006; Postma et al., 2006).  
Schizophrenics often show much higher rates of cigarette smoking when compared to the 
general population, so studies involving nicotine and schizophrenia can be very useful in 
  Effects of Nicotine 15
order to better understand the disease (Postma et al., 2006; Smith, Singh, Infante, 
Khandat, & Kloos, 2002).  Schizophrenics have difficulty ignoring irrelevant sensory 
input, and often show impairment in acoustic prepulse inhibition (PPI).  PPI is 
characterized by a decrease in the magnitude of response to a startling stimulus when the 
stimulus is preceded by a lower intensity, non-startling stimulus (Postma et al., 2006).  In 
schizophrenic patients, the reaction to the startling stimulus is not lessened by the 
prepulse, thus causing an overload of information that would not occur in normal patients 
(Kumari, Soni, Mathew, & Sharma, 2000).   
Nicotine has been shown to enhance PPI in both normal controls and 
schizophrenic patients, and a functional magnetic resonance imaging (fMRI) study 
showed that the increase in PPI as a result of the nicotine appeared largely in the 
hippocampus (Postma et al., 2006).  In addition to improved PPI, nicotine administered 
via nasal spray has been demonstrated to improve cognition (through verbal memory 
tasks and spatial organization tasks) in schizophrenics and has also led to improved 
performance on oculomotor and attention tasks (Depatie et al., 2002; Smith et al., 2002).  
These results suggest that the increase in smoking in schizophrenic patients is possibly a 
form of self-medication, and provides evidence for a schizophrenia treatment involving 
another method of nicotine administration that does not include the added risks associated 
with cigarette smoking.  
Attention Deficit/Hyperactivity Disorder 
Because of the clear evidence that nicotine has a positive effect on attention, 
studies have also been carried out to demonstrate nicotine’s effect on adults with 
Attention Deficit/Hyperactivity Disorder (ADHD).  ADHD is characterized by symptoms 
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of inattention and hyperactivity that are severe enough to interfere with daily life 
(Sharkey & Fitzgerald, 2007).  As would be expected, administration of nicotine to 
ADHD patients leads to improved performance on tasks of attention, such as the 
Conners’ Continuous Performance Test (CPT), and has also been reported to decrease 
reports of depressed mood (Levin et al., 1996; Rezvani & Levin, 2001).  Nicotine patches 
administering 7 mg of nicotine to non-smoking ADHD patients showed an overall 
nicotine-induced improvement on a modified version of the Clinical Global Impressions 
(CGI) scale, as well as improving scores on the CPT (Levin et al., 1996).     
From the numerous studies investigating the administration of nicotine to people 
with diseases affecting different aspects of cognition, it can be inferred that nicotine can 
be extremely beneficial to people suffering from a variety of illnesses.  In illnesses like 
Parkinson’s disease, schizophrenia and ADHD, adult patients have been shown to self 
medicate with cigarettes, and evidence points to this being due to the nicotine they 
receive (Levin, McClernon et al., 2006).  Smoking, however, adds numerous risks due to 
the toxins found in the smoke that cause lung damage and cancer, as well as the addictive 
properties of nicotine when delivered in such high doses (Winger et al., 2004).  Thus, if 
nicotine can be administered in a more controlled and safe manner as a therapeutic agent, 
patients would not have to be subjected to the risks associated with cigarette smoking. 
Animal Models and Working Memory 
Due to experimental limitations in human nicotine studies, much of the 
preliminary and ongoing research regarding nicotine’s effects on cognition has come 
from studies of non-human animals.  Nicotine has been shown to have a significant effect 
on cognition in non-human animals in various behavioral tasks that demonstrate working 
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memory.  Working memory is an updated term for short-term memory, and it involves 
the storage of information that is currently in use, or that is likely to be needed in a short 
amount of time (Hegarty & Waller, 2005; Schumann et al., 2004).  Working memory can 
include verbal (in humans), object, and spatial tasks, and it is relatively easy to test this 
type of memory function in lab animals using object recognition tasks, the Morris Water 
Maze, or the Radial Arm Maze (Hegarty & Waller, 2005; Schumann et al., 2004).  An 
example of nicotine’s effect on working memory can be demonstrated by the 
performance of rats in an object recognition task:  Rats that were given an acute dose of 
nicotine demonstrated improved working memory compared to normal controls due to a 
clear increase in the recognition of an old object vs. a new object (Puma, Deschaux, 
Molimard, & Bizot, 1999).  In addition to this, zebrafish that were exposed to an acute 
dose of nicotine for 3 minutes showed increased performance in a spatial position 
discrimination task (Levin, Limpuangthip et al., 2006).   
One way to demonstrate working memory is to expose rats to the Radial Arm 
Maze (RAM), which consists of a maze with arms extending out from a center (the 
number of arms varies based on the study), and a reward at the end of each arm (usually a 
food treat).  Rats should only venture down each arm once until all rewards are received, 
and any time a rat re-enters an arm, it is marked as an error.  In this way, working 
memory can be assessed by the extent to which the rat remembers what arms it has 
already been down.  In a study assessing the effects of acute and chronic nicotine on 
young and aged rats in the RAM, Levin and Torry (1996) found that the young rats 
treated with chronic nicotine showed an increase in working memory, but the aged rats 
did not show the same increase.  There was no significant improvement in working 
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memory after acute doses of nicotine in the young rats, but there was a pronounced effect 
of the acute administration of nicotine in the aged group (Levin & Torry, 1996).  These 
findings suggest that a chronic dose of nicotine may be more effective in cognitive 
enhancement in young rats, while aged rats may benefit more from acute doses 
administered immediately prior to a task (Levin & Torry, 1996).  These findings contrast 
slightly with the findings of French and colleagues (2006), who tested aged rats with a 
chronic nicotine dose of 0.3 mg/kg in the RAM.  They found nicotine significantly 
increased working memory in these rats, and suggested that the lower dose in aged rats 
helped improve performance due to their decreased metabolism of the nicotine (French, 
Granholm, Moore, Nelson, & Bimonte-Nelson, 2006).  In the Levin and Torry (1996) 
study, the dose given to both groups was 0.5 mg/kg.  It is possible that this dose was 
effective for the young rats, but too much for the old rats when administered chronically.   
Another commonly used method to demonstrate increased cognition in rats 
exposed to nicotine is to test them in the Morris water maze (MWM) to determine their 
cognitive spatial abilities.  The MWM is a large circular maze filled with opaque water, 
and rats (or mice) must locate a hidden platform using spatial cues surrounding the maze 
(Morris, 1984).  At the start, rats are placed on the platform so they can become 
acclimated to the maze and exposed to the spatial cues that surround it.  Then they must 
learn that there is no escape from the maze via the outside walls, and they must utilize the 
spatial cues around the maze to locate the platform.  Full acquisition of the task occurs 
when the swim times decrease and level off, and remain low when the rats are placed at 
varying start locations around the maze (Morris, 1984).  Studies have demonstrated that 
rats differ in performance in the Morris water maze based on age, gender, and sometimes 
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strain (Hansalik, Skalicky, & Viidik, 2006; Topic et al., 2005).  Age differences are 
apparent in that aged rats tend to have more difficulty in the acquisition of the water maze 
task compared to young rats, however according to a study by Topic and colleagues 
(2005), there is considerable variability due to individual differences.  Thus, while most 
aged rats were slower than the young rats, there were some aged rats who had swim times 
that were on par with those of the youngest and fastest rats (Topic et al., 2005).  Early 
training, however, can decrease response times of aged rats compared to aged rats with 
no previous training, suggesting that the MWM is also a tool for assessing long-term 
memory retention (Hansalik et al., 2006). 
In nicotine studies examining spatial learning, the dose administered and length of 
administration prior to training are extremely important.  A study using mice 
demonstrated that a nicotine dose of 0.7 mg/kg/day produced significant impairment in a 
water maze task, but 0.35 mg/kg/day administered intraperitoneally 5 days prior to 
training and throughout training itself produced significantly lower trial latencies (Bernal, 
Vicens, Carrasco, & Redolat, 1999).  Thus, it is important not only to administer a low 
dose of nicotine, but also to administer it a few days prior to the task to allow the drug to 
take its full effect (Bernal et al., 1999).  The extra time needed is most likely due to the 
fact that receptor upregulation, which can enhance the effect the nicotine has on the brain, 
takes some time to occur.  Nicotine doses as low as 0.2 mg/kg have been shown to have 
an effect on both young and older rats, and these studies have also utilized the technique 
of waiting a few days prior to the first acquisition trials in order for the drug to take effect 
(Socci, Sanberg, & Arendash, 1995).  Using a dose of 0.2 mg/kg not only results in 
enhanced water maze acquisition in aged rats, but it also has been shown to improve 
  Effects of Nicotine 20
memory retention in young rats (Socci et al., 1995).   
It has also been reported that high doses of nicotine do not demonstrate nicotine’s 
positive effects due to ACh receptor desensitization.  Receptor desensitization occurs 
when a neurotransmitter binds to a receptor but the ion channel, through which positively 
charged ions would normally travel to lead to an EPSP, remains closed (Benwell et al., 
1995).  Thus, though the neurotransmitter is bound to the receptor, an action potential 
does not occur and the neuron does not fire.  Because of this desensitization (which 
occurs when rats are administered high levels of nicotine that are on par with the amount 
a regular smoker may receive, 1.0 and 4.0 mg/kg/day for this particular study), the effect 
of the nicotine on memory and learning is actually inhibitory (Benwell et al., 1995).  
Lower doses of nicotine, for example, 0.25 mg/kg/day, did not show this desensitization, 
and thus still shows cognitive enhancement in spatial learning studies (Benwell et al., 
1995).   
Long-Term Potentiation 
Studies involving nicotine treatment in working memory tasks are also beneficial 
in that they can provide evidence for nicotine’s inducement of Long Term Potentiation 
(LTP).  As was mentioned earlier, LTP occurs in the hippocampus and results in an 
increase in synaptic firing and effectiveness (Schumann et al., 2004).  LTP is an 
important part of memory formation, and it has been shown to occur throughout the 
neuronal information pathways in the brain (Schumann et al., 2004). This process also 
involves the upregulation of glutamate NMDA receptors, which have been shown to be 
modulated by nicotine in some studies of working memory in rats (Levin, Bettegowda, 
Weaver, & Christopher, 1998).   
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One study looked at nicotine’s effect on LTP in the rat hippocampus by assessing 
its therapeutic effects in rats suffering from working memory impairments.  The working 
memory impairments were induced by stress, and the subcutaneous administration of 1 
mg/kg of nicotine prevented the memory impairments associated with the stressor 
(Aleisa, Alzoubi, Gerges, & Alkadhi, 2006).  The nicotine served to normalize the LTP 
that had been reduced in the stressed rats treated with saline.  This suggests that nicotine 
does have neuroprotective effects regarding memory and learning, so much so that it can 
counteract the impact of a stressor in rats (Aleisa et al., 2006).  The control rats in the 
study that were not exposed to the stressor but received nicotine treatment did not show 
any learning or memory improvement, however this could be due to the extremely high 
dose (1 mg/kg) of nicotine that was administered.  It has already been demonstrated that 
high doses can show water maze impairment, so it is possible that such a high dose is 
only necessary to reverse the effects of cognitive impairment, not to enhance the 
performance of otherwise normal rats (Bernal et al., 1999). 
It has also been demonstrated that nicotine can attenuate working memory 
impairments caused by dizocilpine, an NMDA glutamate receptor antagonist, providing 
more evidence for nicotine’s neuroprotective effects (Levin, Bettegowda et al., 1998).  
NMDA glutamate receptors are known to be upregulated as a result of LTP, so the 
attenuation of these impairments could be due to an increase of LTP as induced by the 
nicotine.  Because the nicotine stimulated the release of glutamate, it was able to 
counteract the drug and reverse the working memory impairments, though it did not 
increase performance in the radial arm maze.  When the dose of nicotine (0.4 mg/kg) was 
given without the dizocilpine, an increase in maze performance was also not detected—it 
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is possible that this dose was too high to produce positive effects, as it has been 
demonstrated that a dose of 0.7 mg/kg in mice actually causes impairments in spatial 
learning tasks (Bernal et al., 1999; Levin, Bettegowda et al., 1998).  In a later study 
involving dizocilpine and nicotine, the nicotine dose of 0.4 mg/kg led to inconclusive 
results regarding its neuroprotective effects.  This suggests that 0.4 mg/kg may be at 
some kind of dose threshold where the effects of the nicotine switch from positive to 
negative (Levin et al., 2003).   
Neurogenesis 
 In past studies demonstrating nicotine’s attenuation of working memory 
impairments, a case has been made that nicotine can be neuroprotective, meaning it 
minimizes the damage done by certain drugs or events by stimulating the release of 
neurotransmitters such as glutamate or dopamine (Levin, Bettegowda et al., 1998).  
Despite this, a study has indicated that nicotine actually decreases neurogenesis in the 
brain when self-administered by rats (Abrous et al., 2002).  However, in this study, the 
self-administration aspect led rats to have plasma nicotine levels that were extremely high 
and equivalent to those of smokers—the rats in cognitive enhancement studies as well as 
humans in controlled nicotine patch studies do not receive such high levels of nicotine 
(Abrous et al., 2002).  It has already been reported that such high nicotine levels 
desensitize important receptors involved with the release of both glutamate and 
dopamine, neurotransmitters essential to memory and learning (Benwell et al., 1995).  
For this reason, it makes sense that large amounts of nicotine may actually decrease 
neurogenesis in the brain. 
Studies employing the use of bromodeoxyuridine (BrdU) are essential in 
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demonstrating the effects of spatial learning tasks on neurogenesis, and can indicate 
whether nicotine has any effect on the cell proliferation.  When injected intraperitoneally, 
BrdU incorporates into the DNA of all cells undergoing synthesis at the time of learning.  
The BrdU stays in these cells and can be detected post-mortem through 
immunohistochemical procedures (Cooper-Kuhn & Kuhn, 2002).  It has been 
demonstrated that an increase in newly-generated cells in the hippocampus occurs due to 
the process of learning itself—not just training (Dalla, Bangasser, Edgecomb, & Shors, 
2007).  Even when the task was not hippocampus dependent, rats that “learned well,” that 
is, that demonstrated a high acquisition of the task after its completion, showed increased 
cell proliferation compared to rats that did not learn well, thus emphasizing the 
importance of learning rather than training (Dalla et al., 2007).  BrdU studies have also 
clearly shown that neurogenesis decreases significantly from adolescence to adulthood, 
though neurogenesis in the hippocampus is still apparent in adults as a result of certain 
tasks involving learning (He & Crews, 2007).  Though the cell growth seen as a result of 
the Morris water maze task is generally attributed to the learning that occurs during the 
late phase of this task, there is also evidence that exercise can increase cell proliferation 
as well (van Praag, Kempermann, & Gage, 1999).  This suggests that tasks involving 
exercise, such as the Morris water maze, could be even more indicative of cell 
proliferation in the hippocampus.   
Morris water maze studies involving BrdU injections can provide useful results 
regarding neurogenesis in the hippocampus as a result of the learning that occurs during 
the task.  In one Morris water maze BrdU study, the early phase of learning, in which 
there is a rapid improvement in performance, did not produce significant cell 
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proliferation, while the late phase of learning, during which the highest point of 
performance is reached, demonstrated a significant increase in the number of newly 
generated cells (Dobrossy et al., 2003).  This was thought to potentially be due to the 
stress of the early phase of learning, in which rats were becoming acclimated to the 
task—for this reason, perhaps, neurogenesis was dampened at that time (Dobrossy et al., 
2003).  Neurogenesis in the late phase, it was hypothesized, could indicate that the 
dentate gyrus of the hippocampus was available for the integration of new information 
and the storage of new memories at that phase of learning (Dobrossy et al., 2003).   
Studies using lower doses of nicotine in tasks that are known to produce 
neurogenesis in the brain, particularly in the hippocampus, have shown that low doses of 
nicotine do not have a detrimental effect on neurogenesis (Scerri, Stewart, Breen, & 
Balfour, 2006).  In accordance with the findings of previous studies, Scerri and 
colleagues (2006) concluded that a nicotine dose of 0.4 mg/kg per day had an adverse 
effect on neurogenesis (as demonstrated by a BrdU investigation), but rats receiving 0.25 
mg/kg per day showed an increase in cell proliferation in response to the Morris water 
maze task.  This study provides further evidence that learning associated with the Morris 
water maze task can be demonstrated clearly in the dentate gyrus of the hippocampus, 
and that nicotine may have a positive impact on the cell proliferation that occurs there 
(Scerri et al., 2006).   
c-Fos Expression 
 In addition to increased cell proliferation, it has been widely reported that nicotine 
produces an increase in c-Fos expression in various areas of the brain (Guan, Kramer, 
Bellinger, Wellman, & Kramer, 2004; McCormick & Ibrahim, 2007; Panagis, Nisell, 
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Nomikos, Chergui, & Svensson, 1996; Salminen, Lahtinen, & Ahtee, 1996).  c-Fos is a 
protein that indicates neuronal activation, and it has often been studied in relation to 
stress (Kovacs, 1998; McCormick & Ibrahim, 2007).  In a study combining stressors with 
nicotine treatment in adolescent male and female rats, it was found that males showed an 
increase in c-Fos in the hypothalamus while females did not, and chronic nicotine groups 
showed more c-Fos expression than did acute nicotine groups (McCormick & Ibrahim, 
2007).  From these results, it can be hypothesized that nicotine must be chronically 
present in the system in order to have an effect on c-Fos expression in the brain.  It has 
also been found that nicotine significantly increases c-Fos expression in brain areas 
specifically related to stress, such as the paraventricular hypothalamic nucleus and the 
supraoptic nucleus (Salminen et al., 1996).    
 The rate of nicotine delivery can also have an effect on c-Fos expression (Samaha 
et al., 2005).  In one study, rats were infused with either 25 or 50 µg/kg nicotine in a time 
span of 5, 25, or 100 seconds.  The results showed that c-Fos expression and receptor 
sensitization were highest when the infusion rates were fastest.  High administration rates 
are thought to be central to the addictive properties of nicotine, and perhaps the increase 
in c-Fos expression is a result of the rapidly increasing occupancy of nicotinic receptors 
that occurs when nicotine is delivered at a fast rate (Samaha et al., 2005).   
 Nicotine can also cause Fos increases in areas of the brain specifically related to 
dopamine transmission, such as the nucleus accumbens and the caudate-putamen.  In a 
study looking at both c-Fos and ∆FosB (another member of the Fos family that stays in 
the brain longer and has been linked to drug addiction), nicotine was shown to increase 
both Fos types in these dopaminergic brain areas, providing further support for nicotine’s 
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role in increasing dopamine transmission (Marttila, Raattamaa, & Ahtee, 2006).  The 
increase that nicotine causes in locomotor activity, also known as behavioral 
sensitization, has also been related to an increase in Fos in the nucleus accumbens, the 
striatum, and the ventral tegmental area, again providing support for nicotine’s role in the 
dopamine release process, and providing further evidence for its rewarding properties 
(Shim et al., 2001).   
 Increased c-Fos expression in nicotine studies is also dependent on the nicotine 
dose used.  One study found that a nicotine dose of 2 mg/kg showed the most dramatic 
expression of c-Fos in the brain, while the lower doses of 0.5 mg/kg and 1mg/kg showed 
minimal increase in c-Fos (though these doses did still produce an increase when 
compared to normal controls) (Ren & Sagar, 1992).  Other studies have shown an 
increase in c-Fos expression in their brain areas of interest (for example, the 
hypothalamus, the visual pathways, the striatum) using doses of 0.4 mg/kg, (Shim et al., 
2001), 0.5 mg/kg (McCormick & Ibrahim, 2007), and 1mg/kg (Salminen et al., 1996).  
Though these doses are slightly higher than those used in spatial learning studies, the fact 
that they produce c-Fos expression suggests that lower doses may still lead to an increase 
in expression when compared to normal controls.   
 The fact that chronic nicotine shows an increase in c-Fos in certain brain areas 
provides support for the idea that neurons may undergo changes in gene expression due 
to nicotine exposure (Ren & Sagar, 1992).  This alteration of neuronal gene expression, 
which could potentially be long-term, would be beneficial to people suffering from 
diseases that affect cognition because it could mean an increase in nAChrs, which would 
increase their cognition and potentially delay the onset of cognitive decline (Ren & 
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Sagar, 1992). 
 The purpose of the current study was to assess the effects of a chronic dose of 
nicotine on the ability of rats to acquire the Morris water maze task in adolescence and 
adulthood.  Previous studies of chronic nicotine administration have indicated that doses 
around 0.2 mg/kg serve to increase cognitive functioning, and that higher doses run the 
risk of adversely affecting maze performance (Bernal et al., 1999; French et al., 2006; 
Socci et al., 1995).  For this reason, we used 0.2 mg/kg as our dose for rats of all age 
groups.   
 Because most of the previous studies involve specifically young or aged rats, this 
study was unique in that it examined the effects of nicotine on the same rats in 
adolescence (Phase 1) and adulthood (Phase 2).  The schedule of nicotine was also varied 
based on the groups.  There were four main groups: rats that received nicotine in Phase 1 
during adolescence and nicotine again in Phase 2 when they reached adulthood (N/N), 
rats that received nicotine in Phase 1 and saline in Phase 2 (N/S), rats that received saline 
in Phase 1 and nicotine in Phase 2 (S/N), and rats that received saline in Phases 1 and 2 
(S/S).  In Phase 1, rats were trained in the Morris water maze while receiving either 0.2 
mg/kg of nicotine or saline for 2 weeks, and then nicotine or saline administration was 
ceased until four months later.  At this time, drug treatment was resumed based on the 
group, and Morris water maze testing was repeated in the same fashion.  Additionally, 
Bromodeoxyuridine (BrdU) injections were introduced into the study during the last two 
days of Phase 2 acquisition in order to view possible neurogenesis as a result of the 
nicotine exposure and water maze training (Scerri et al., 2006). 
 Though this study involved nicotine cessation after a 2-week period of chronic 
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nicotine administration, the rats were not expected to experience serious withdrawal 
symptoms.  A study investigating withdrawal from chronic nicotine showed that even 
after an extremely high dose (22.2 mg), withdrawal symptoms in adolescent rats were 
minimal, even after the immediate introduction of a nicotinic agonist (Wilmouth & Spear, 
2006).  Adult rats showed minor withdrawal symptoms that abated shortly after nicotine 
cessation (Wilmouth & Spear, 2006).  This finding, coupled with the fact that the dose 
was significantly higher in these studies, suggests that the rats in the present study were 
not in danger of severe withdrawal symptoms in the interim between phases.   
 The purpose of the varying nicotine schedules was to determine whether learning 
was state dependent (for the N/N group), whether early experience had a greater effect on 
task acquisition (for the N/S group), or whether the effect of nicotine was more 
pronounced in older rats (for the S/N group).  The rats that received saline in both phases 
served as a control for this experiment.  It was expected that, in both phases, nicotine rats 
would perform better than saline rats in the Morris water maze.  Due to the previous 
training that the rats received in Phase 1, it was expected that reaction times would be 
faster overall in Phase 2 during the re-acquisition of the task, however it was 
hypothesized that rats receiving nicotine in Phase 2 would re-acquire the task faster than 
rats not receiving nicotine, and that rats receiving nicotine in both phases would be better 
at the task overall (Hansalik et al., 2006). 
 It was also expected that rats in all groups would show an increase in cell 
proliferation in the hippocampus due to the water maze task, and that the Phase 2 nicotine 
rats would have more BrdU expression than the saline rats due to previous studies 
suggesting nicotine is neuroprotective and involves nAChR upregulation (Dobrossy et 
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al., 2003; Wang et al., 2008).  We also tested for c-Fos in the hippocampus following the 
last day of training in the second phase of testing for all rats.  Based on previous studies 
indicating that chronic nicotine at doses of 0.5 mg/kg to 2 mg/kg increase c-Fos 
expression in certain brain areas, we expected c-Fos levels to be elevated in rats receiving 
nicotine in Phase 2 (McCormick & Ibrahim, 2007).   
We specifically looked at c-Fos expression in the dentate gyrus of the 
hippocampus.  A previous study examining nicotine’s effect on c-Fos in the pigeon brain 
reported the hippocampus to be one of the greatest sites of c-Fos expression, however to 
our knowledge a study investigating c-Fos expression in the rat hippocampus following 
nicotine exposure and a spatial learning task has not previously been attempted 
(Chadman, Woods, & Stitzel, 2007).  For this reason, the present research provides 
important results regarding the effect of nicotine on c-Fos in the hippocampus and the 
implications this has regarding spatial learning.  A significant c-Fos increase in the 
hippocampus may provide even further evidence that nicotine has a significant effect on 
cell growth and receptor upregulation in this brain area, as c-Fos is generally an indicator 
of the beginnings of neuronal change and activity (McCormick & Ibrahim, 2007; Ren & 
Sagar, 1992). 
Method 
Subjects 
 Subjects included 50 male Fisher-344 rats born at the Charles River Laboratories 
in Stoneridge, NY, USA.  Rats from all cohorts were 6 weeks old on arrival.  The study 
began 2 weeks later, at which time rats in Cohort 1 (numbers 1-16) weighed between 160 
g and 185 g, rats in Cohort 2 (numbers 17-35) weighed between 155 g and 180 g, and rats 
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in Cohort 3 (numbers 36-50) weighed between 150 g and 180 g.  Five months later 
during Phase 2 of the experiment, Cohort 1 weighed between 305 g and 340 g, and 
Cohort 2 weighed between 300 g and 345 g, with one rat weighing 276 g.   
 Rats were housed 3 or 4 to a clear plastic cage measuring 19 x 9 x 9 in.  They 
were given regular shavings, water, and rat chow.  Some of the rats from Cohorts 1 and 2 
were given wet food along with the dry food a few months into the study due to slightly 
decreased weight that may have been the result of a mouth infection.  Rats were also 
given a square red Plexiglas tube to use as a shelter. 
 Procedures were approved by the Connecticut College Animal Care and Use 
Committee in accordance with the guidelines of the USDA and the Office of Laboratory 
Animal Welfare. 
Apparatus 
 Alzet osmotic mini-pumps (model 2004, Braintree Scientific, Braintree, MA) 
were used to administer a chronic dose of 0.2 mg/kg of nicotine or saline per day for a 2-
week period.  
 Activity levels were recorded in an activity box measuring 42 x 45 cm on the 
inside and 11 cm high, with a normal rat cage, measuring 42 x 22 cm and 21 cm high, 
inside of it.  The normal cage was made of transparent plastic and had a metal lid and 
wood shavings for bedding.  The activity box surrounding the cage was made of metal 
and measured the activity of the rat.  There was a light beam on one side of the cage 
projecting to the other side, which measured beam crossings (the amount of times the rat 
interrupted the light).  This provided a quantitative measurement of the rat’s movements.   
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 Spatial learning was tested using a Morris water maze.  The maze was a large 
white plastic tub that was 4 ft in diameter.  The water level was kept at 13 in, with the 
platform approximately 0.5 in below the water level. The platform was a tall Plexiglas 
tube with a petri dish fitted to the top.  A white washcloth was attached to the top of the 
platform with a rubber band.  The platform was kept stationary, 11 in from the right side 
of the maze, using a weight at the base.  The water was made opaque with white tempera 
paint, which was mixed thoroughly in the water prior to each acquisition and test day.  
The water was kept at 20 °C during all experimental trials.   
 The maze was in a rectangular shaped room with white walls and various 
stationary visual cues surrounding it.  The visual cues included rectangular pieces of 
construction paper with different shapes (circles, a star, stripes) of contrasting color on 
top of them.  The metal temperature gauge and hose, as well as the open door and the 
experimenter’s position also acted as visual cues, and remained constant during the 
experiment.  The maze was 10.5 in away from the two longer walls, and 17 in away from 
the shorter wall farthest from the door to the room. 
Procedure 
 Rats were allowed to acclimate to their new surroundings for one week prior to 
being handled and weighed for the first time.  The rats were handled for approximately 3 
minutes each on at least two separate occasions prior to their first day of surgery.  Weight 
measurements (in grams) were taken two days prior to surgery, as well as the day of 
surgery in all cases, in order to ensure the rats were gaining weight at a normal pace and 
to make the measurement of the necessary anesthetic as accurate as possible.  Activity 
levels were taken on the day of the last surgery for all groups in order to determine 
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possible changes in locomotion in the nicotine rats.   The early phase of acquisition trials 
in which Cohorts 1 and 2 (these two cohorts make up what is later referred to as the dual-
phase cohort) were first exposed to the experimental procedure was considered Phase 1.  
Cohort 1 initially contained 16 rats, however due to some complications with the pumps 
the data from 2 of the rats was not used.  Cohort 2, containing rats that arrived one week 
after Cohort 1 with all of the same specifications, included 18 rats.  One rat died during 
the surgical procedure, so its data was not used in the experiment.  At this time, rats were 
given either nicotine or saline for the experimental procedure.  See Table 1 for a 
description of the drug treatments and number of subjects in each group.   
 During Phase 2 of testing, rats in the dual-phase cohort were broken up into four 
groups, N/N, N/S, S/N, and S/S, depending on what drug treatment they received in 
Phases 1 and 2 (see Table 1).  The purpose of the N/N rats was to indicate whether 
acquisition of the procedure was state-dependent.  The N/S rats were to demonstrate 
whether early experience had a greater effect on task acquisition than the nicotine itself.  
The S/N rats were to demonstrate whether the effect of the nicotine would be more 
pronounced in older rats, and the S/S group acted as a control for the three other groups.   
 The 16 rats in Cohort 3 (the single-phase cohort) contained the same 
specifications as all previous rats, and underwent the same procedure, with 8 receiving 
nicotine pumps and 8 receiving saline pumps.  One rat died during the procedure, leaving 
7 nicotine rats and 8 saline rats.  After one phase of acquisition and test trials, these 
animals were sacrificed and their brains were examined for neurogenesis (as evidenced 
by BrdU) and c-Fos in the hippocampus.  In this way they acted as a control for age, as 
their results were expected to provide insight into the c-Fos and BrdU expression that 
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might occur in adolescent rats as a result of nicotine exposure.  They did not undergo a 
second testing phase. 
 Approximately 24 hours prior to the surgery the pumps were set up following the 
procedure as outlined by the Alzet company.  The nicotine was mixed using 0.2859 
grams of nicotine per 3 ml of saline.  This concentration allowed the animals to receive 
0.2 mg/kg per .29 µl nicotine base per day, while the control animals would receive an 
equal volume of vehicle (saline) per day.  In order to fill the pumps, the empty pump was 
first weighed along with the flow moderator.  Solution was drawn into a 1 ml syringe and 
a 27 gauge filling tube (provided by the Alzet company) was fit to the end of it.  The 
empty pump was held upright and filled slowly, ensuring there were no air bubbles in the 
pump.  When the solution appeared at the outlet of the pump, the filling tube was 
removed and excess solution was wiped off.  The flow moderator was then inserted until 
it was flush with the pump, and the displaced solution was wiped off.  The pump was 
then weighed again, ensuring that the difference in the weight from the empty pump gave 
the proper net solution of the pump, 30 μl.  Pumps were then incubated in sterile saline 
and allowed to equilibrate at 37 °C overnight.   
 On the day of surgery, all animals were weighed in order to ensure an accurate 
dosage of anesthetic.  The anesthetic was prepared by mixing 1.95 ml of xylazine and 1.8 
ml of ketamine.  In order to determine the specific amount of anesthetic necessary for 
each rat, 1.25 ml was multiplied by the most recent weight measurement in kilograms.  
The result, usually hovering around 0.2 ml, was administered intraperitoneally and the 
rats were put in a covered cage as the drug took effect.  Once the rat was asleep, a small 
area between the shoulder blades was shaved, and a vertical incision was made in the 
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skin.  The pump was then inserted subcutaneously.  The wound was then closed with two 
metal clips, and the rat was placed in another covered cage until the anesthetic wore off.  
This procedure was repeated for each rat. 
 During the first surgeries for Cohort 1, the pumps were inserted with the top of 
the pump facing the wound.  Due to the complications of a few of the pumps coming out 
because of excessive scratching, it was determined that the release of nicotine may have 
been irritating the wound.  Thus, all other surgeries were conducted by inserting the top 
of the pump first. 
 Two days after the surgery all rats were weighed to ensure they did not lose a 
significant amount of weight as a result of the drug.  The rats were given 7 days prior to 
the acquisition trials for the drug to begin to take effect.  After this time had elapsed, all 
rats were tested in the Morris water maze. 
Testing began daily at 4:00 pm, and usually lasted between 1.25 and 2 hours.  
Prior to the first trial on Day 1 of acquisition, all rats were placed on the platform for 60 
seconds so they could become acclimated to their surroundings.  During the acquisition 
trials, rats were positioned at start location 1 (see Figure 1) and a time measurement was 
taken with a stopwatch to measure how long it took them to reach the platform.  If any rat 
failed to reach the platform after 60 seconds of swimming during any given trial, the rat 
was removed from the maze and placed on the platform for another 60 seconds.  
Acquisition involved five trials from start location 1 per day for five consecutive 
days.  Rats were tested by cage, so trials were alternated between 4 rats at a time in order 
to avoid fatigue from completing multiple trials per rat in succession.  After the fifth day 
of acquisition trials there were two days without any trials, followed by one day of test 
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trials (see Table 2).  During the testing day, the first trial was at the familiar start location 
(start location 1), and the remaining 4 trials began at varying start locations around the 
maze (see Figure 1 for a diagram of the maze and start locations).  These start locations 
remained constant throughout the study.   
It should be noted that during the first day of acquisition trials for Cohort 1 in 
Phase 1 of testing, 10 acquisition trials were taken per rat (as opposed to 5).  It was 
determined that this number was too high, as latencies began to increase toward the end 
of the acquisition period.  The increase was most likely due to fatigue, and thus all 
acquisition days following that first day involved only five trials, and only the first five 
trials from acquisition day 1 for Cohort 1 were used in the data analysis. 
 After the week of testing was over, rats were weighed, activity levels were 
recorded in an activity box for five minutes, and then they were anesthetized using the 
same procedure as outlined previously.  The pumps were removed and the rats from the 
dual-phase cohort were kept until Phase 2 of testing, which occurred four months later.  
These rats were weighed once a week in between testing phases. 
 Acquisition and testing for the single-phase cohort and Phase 2 of the dual-phase 
cohort were subject to a slightly different procedure.  Surgery was performed on these 
rats as per usual, and acquisition trials began one week following the procedure.  The 
procedure for acquisition trial days 1-4 were identical to those of Phase 1 of the dual-
phase cohort, however after the fourth day one day was skipped, and the last day of 
acquisition was on the sixth day of the experiment.  The test trials were on the day 
immediately following the last day of acquisition (day 7), in order to allow for perfusion 
of rats that coincided with the test trials and the injection of BrdU (see Table 2 for the full 
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experimental schedule).   This change in procedure was due to complications with the 
BrdU, however it was not expected that any significant difference would arise due to this 
change.  The order in which the trials occurred and the small timing changes of the 
testing trials were not expected to have any effect on the ability of the rats to perform the 
task and to recall it during testing.   
 BrdU was introduced during Phase 2 acquisition trials for the dual-phase cohort, 
and during the acquisition trials of the single-phase cohort.  BrdU was mixed in a 
concentration of 25 mg/ml in physiological saline.  It was necessary to warm the solution 
in order for the BrdU to dissolve.  Once the BrdU was in solution, rats were weighed, the 
proper amount for injection (2 ml/kg) was calculated, and rats were injected at roughly 
4:30 pm during the free day between acquisition days 4 and 5.  The second BrdU 
injection occurred 30 minutes prior to acquisition trials on acquisition day 5, which was 
one day prior to test trials.  Two rats from the dual-phase cohort did not receive the BrdU 
injection, as they were aggressive and difficult to inject. 
 Rats were perfused 90 minutes after their last test trial in order to preserve the 
brains to look at c-Fos and incorporation of BrdU in the hippocampus.  This process 
involved euthanizing the rat and perfusing the body with the fixative 4% PFA, then 
removing the brain and soaking it in the fixative overnight.  The following day, the brain 
tissue was transferred to a 30% sucrose mixture.  Using a cryostat, the brain tissue for 
each rat was then frozen and sliced at 25μm through the dentate gyrus of the 
hippocampus.  The sections of brain tissue were then placed in a preserving solution, and 
3 slices from each rat were selected to be stained and examined further for c-Fos content.  
A separate set of sections was selected to be stained for BrdU incorporation.  The 
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sections of tissue were chosen based on their representation of the dentate gyrus.   A rat 
brain atlas was utilized to determine which sections of the brain tissue were to be 
examined (Paxinos & Watson, 1998).  One rostral (AP –3.30 mm in reference to 
Bregma), middle (AP –2.12 mm in reference to Bregma) and caudal (AP –3.6 mm in 
reference to Bregma) section was taken for each rat to represent different sections of the 
hippocampus (Paxinos & Watson, 1998).  
c-Fos Immunohistochemistry 
The c-Fos staining procedure involved washing the selected pieces of tissue for 30 
minutes and the placing them in a solution containing the 10 antibody (rabbit anti-Fos 
polyclonal IgG, Santa Cruz Lot #c270) that binds to segments of the c-Fos protein.  The 
concentration was 1:8000, diluted in 50 ml of blocking solution (98.75mL 0.01 M PBS, 1 
ml normal goat serum, 1 g bovine serum albumin, 0.25 ml 30% Triton X100).  They were 
left in this solution overnight, and then rinsed and placed in a solution containing 
biotinylated 20 antibodies (goat anti-rabbit polyclonal IgG, Jackson Laboratories) that 
recognize the 10 antibody.  This concentration was 1:200 diluted in 50 ml of blocking 
solution.  Two hours later the tissue was rinsed again and avidin-biotin molecules 
complexed with horseradish peroxidase diluted in 50 ml of 0.01 M PBS were added.  
These molecules bind to the biotin molecules on the antibodies.  After one hour enhanced 
DAB (Diaminobenzidine enhanced with nickel and cobalt) diluted in 50 ml of 0.1 M PB 
was added, which interacted with the peroxidase to form a precipitate that allows for the 
visualization of the c-Fos location.   
After being left to dry overnight, the slides were coverslipped and viewed under a 
microscope.  A 240 x 152 µm portion of the dentate gyrus was viewed in each section of 
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tissue for each rat.  The dimensions of this area were kept constant across rats.  For the 
middle and caudal sections, the portion of the dentate gyrus that was measured for c-Fos 
content was the hilus.  For the rostral sections, the lower portion of the dentate gyrus was 
measured, and this location was kept constant across caudal sections.  Only the darkest 
particles in each section were counted, ensuring that only Fos-positive nuclei were being 
measured.   
BrdU Immunohistochemistry 
 The BrdU staining procedure was performed as outlined in the kit from Chemicon 
International.  The procedure first involved the deparaffinization of the control tissue 
included with the kit.  This involved soaking the paraffinated slides in xylene, and then 
washing them in 100%, 90%, 80%, and 70% ethyl alcohol for 3 minutes each.  
Afterwards tissue was washed in PBS for 3 minutes.  Control slides and experimental 
slides were soaked in Quenching Solution (dilute 30% hydrogen peroxide 1:10 in 
methanol) for 10 minutes, and then washed with PBS for 2 minutes.  Two drops of 0.2% 
Trypsin Solution were added to control slides and slides were incubated at room 
temperature for 10 minutes.  Slides were then washed for 3 minutes in distilled water.  
Denaturing Solution was added to all slides and they were allowed to incubate at room 
temperature for 30 minutes, followed by 2 PBS washes for 2 minutes each.  Blocking 
solution was then added to each slide, and they incubated for 10 minutes.  Slides were 
blotted dry on a paper towel before the Detector Antibody was added, and then were left 
to incubate for 60 minutes.  Following incubation slides were washed twice with PBS, 2 
minutes per wash.   
Streptavidin-HRP Conjugate was then added to each slide and slides were 
  Effects of Nicotine 39
incubated at room temperature for 10 minutes.  This was followed by two 2-minute 
washes in PBS.  DAB concentrate was added to slides at a concentration of 1 µl for every 
29 µl of Substrate Reaction Buffer.  Slides were allowed to incubate for 10 minutes and 
were washed with distilled water for 2 minutes.  Hematoxylin Counterstain was added to 
all slides and left to incubate for less than a minute.  Slides were briefly washed with 
distilled water and then incubated in PBS for 1 minute until the color turned blue.  Slides 
were washed for 2 minutes in distilled water.  To prepare for coverslipping, slides were 
incubated in 90% ethanol for 30 seconds, 100% ethanol for 30 seconds, and xylene for 30 
seconds.  Slides were coverslipped and left to dry overnight.   
Results 
Weight/activity level analysis 
 Weights and activity levels were monitored throughout the study to determine if 
the administration of chronic nicotine led to significant weight loss or increased 
locomotion.  One-way ANOVAs were conducted for the weights of the dual-phase cohort 
after they had been exposed to nicotine or saline for 14 days in Phase 1 and in Phase 2.  
The results for these rats were not significant, indicating that after 14 days of nicotine 
administration in both phases, no significant differences arose between the weights of the 
saline and nicotine rats.  The single-phase cohort also did not demonstrate significant 
differences between the weights of rats receiving nicotine and rats receiving saline.   
One-way ANOVAs were also conducted for the activity levels of the dual-phase 
cohort (in Phases 1 and 2) and the single-phase cohort after they received nicotine or 
saline for 14 days to view potential increases in locomotion as a result of nicotine 
administration.  No significant results were found between the activity levels of the 
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nicotine or saline rats in any cohort.  This shows that the nicotine did not have a 
significant effect on the locomotion of the rats during the experiment.   
Spatial learning analysis 
 Single-phase cohort 
 A repeated measures analysis using a 2 (group) x 5 (days) mixed design ANOVA 
was conducted with trial totals across the 5 days of acquisition.  Trial totals were 
calculated by adding the latencies of trials 1 through 5 for each rat in each day.  The 
independent variable was the drug condition and the dependent variables were the trial 
latencies.   
 The effect of condition across days using trial totals was not significant, 
indicating that condition had no significant effect on trial totals across days 1 through 5.  
However, an effect of training could be found by comparing the trial latencies across 
days for all rats, regardless of drug condition.  In the analysis of trial totals, a significant 
effect of training was seen across the days of the acquisition period, F(4, 52) = 21.49, p < 
.001.  This shows that the rats learned the task due to an overall decrease in trial latencies.   
 Performance between groups on each acquisition day was assessed using a 2 
(group) x 5 (trials) mixed design analysis of variance (ANOVA), which was conducted 
with repeated measures across the 5 trials per day.  The effect of condition (nicotine or 
saline) on trial latencies for each individual day was not significant, indicating no 
significant difference between rats treated with nicotine and rats treated with saline.  In 
the analyses of individual days, however, a significant effect of training was found for 
acquisition days 1 (F(4, 52) = 4.18, p = .005), and 3 (F(4, 52) = 3.18, p = .02), and effects 
for days 2, 4, and 5 were not significant (see Figure 2 for a graph of mean trial latencies 
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in acquisition days 1-5 that demonstrate the learning of the task).  This indicates that the 
majority of learning occurred across trials on days 1 and 3, during the earlier days of 
acquisition.   
 A one-way ANOVA was conducted for test trial totals (the sum of all test trials 
for each rat), and a separate ANOVA was conducted for test trial averages (the sum of all 
test trials for each rat divided by the number of trials).  The effect of condition for the 
trial totals and averages were not significant, however the means for saline (M = 30.02) 
and nicotine (M = 26.52) rats indicate a trend toward significance (see Figure 3 for a 
graph of test trial averages at each start location).  Additionally, five one-way ANOVAs 
were conducted for each test trial (each test trial was at a different start location, and 
there were 5 in total) in order to view possible effects of condition.  Effects of condition 
for test trials 1 through 5 were not significant, indicating that the nicotine did not produce 
a significant decrease in trial latencies in adolescent rats.     
 Dual-phase cohort  
 Phase 1 
 Statistical analyses for Phase 1 acquisition were conducted using the same 
procedure as outlined for the single-phase cohort.  A repeated measures analysis using a 2 
(group) x 5 (days) mixed design ANOVA was conducted with trial totals across the 5 
days of acquisition.  Trial totals were calculated by adding the latencies of trials 1 
through 5 for each rat in each day.  Again, the independent variable was the drug 
condition and the dependent variables were the trial latencies.   
 The results for this group of adolescent rats in acquisition coincided with those of 
the single-phase cohort adolescent rats.  The effect of condition across days using trial 
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totals was not significant, confirming that nicotine did not have a significant effect on 
trial totals across acquisition days 1 through 5.  The effect of training for trial totals 
across days 1 through 5 was significant, F(4, 116) = 57.54, p < .001, indicating learning 
due to a decrease in latency totals across acquisition days in Phase 1 acquisition.   
Performance between groups on each acquisition day was assessed using a 2 
(group) x 5 (trials) mixed design ANOVA, which was conducted with repeated measures 
across the 5 trials per day.  The effect of condition (nicotine or saline) on trial latencies 
for individual days 1, 2, 4, and 5 were not significant, indicating the nicotine did not have 
a significant effect in the adolescent rats in Phase 1 of acquisition.  There was a 
significant effect of condition seen for Day 3, however, indicating a decrease in trial 
latencies in the nicotine treated rats, F(4, 116) = 2.56, p = .04.  Additionally, there was a 
significant effect of training in day 1, F(4, 116) = 7.22, p < .001, and day 2, F(4, 116) = 
2.95, p = .02, indicating learning via a decrease in latencies across trials in both 
conditions.  The effects of training on days 3, 4, and 5 were not significant, coinciding 
with the results from the single-phase cohort suggesting that the bulk of learning occurs 
during the early days of acquisition (see Figure 4 for a graph of mean trial latencies in 
Phase 1 acquisition days 1-5).   
 A one-way ANOVA was conducted for test trial totals, and a separate ANOVA 
was conducted for test trial averages.  Effects for trial totals and averages were not 
significant, however the averages for trial totals in the saline (M = 26.42) and nicotine (M 
= 21.31) conditions indicate a clear trend toward significance (see Figure 5 for a graph of 
Phase 1 test trial averages).  Additionally, as in the single-phase cohort, five one-way 
ANOVAs were conducted for each test trial in Phase 1.  Effects of condition for trials 1 
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through 5 were not significant, indicating that the nicotine did not produce a significant 
difference in latencies in each trial.   
 Phase 2  
 Statistical analyses for Phase 2 acquisition were conducted in the same fashion as 
in Phase 1 and the single-phase cohort.  A repeated measures analysis using a 2 (group) x 
5 (days) mixed design ANOVA was conducted with trial totals across the 5 days of 
acquisition.  Trial totals were calculated by adding the latencies of trials 1 through 5 for 
each rat in each day.  The independent variable was condition and the dependent 
variables were the trial latencies. 
 In the analysis of trial totals, an effect of condition across days was not seen, 
indicating that nicotine did not have a significant effect on trial totals across acquisition 
days 1 through 5.  A significant effect of training was seen for trial totals across days, 
F(4, 116) = 9.86, p < .001.  This demonstrates an effect of the task, as latencies in both 
conditions decreased as a result of training. 
The performance between groups on each acquisition day was assessed using a 2 
(group) x 5 (trials) mixed design ANOVA, which was conducted with repeated measures 
across the 5 trials per day.  An effect of condition (nicotine or saline) for individual days 
1 through 5 was not seen, indicating that in the second phase of acquisition, condition did 
not have a significant effect on trial latencies.  The effects of training for day 1, F(4, 116) 
= 8.86, p < .001, and day 2, F(4, 116) = 4.82, p < .001, were significant, indicating a 
decrease in latencies due to learning of the task (see Figure 6 for a graph of Phase 2 
acquisition trials as compared to Phase 1 acquisition trials).  The effects of training for 
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days 3, 4, and 5 were not significant, indicating again that the bulk of learning occurred 
in the early days of acquisition.   
A paired samples t-test was conducted to determine differences between the first 
trial in Phase 1 acquisition and the first trial in Phase 2 acquisition.  This provided insight 
as to whether previous training had a significant effect on trial latencies in Phase 2 
acquisition, regardless of group.  The difference between the two trials was significant, 
t(1, 30) = 9.39, p < .001, indicating that trial latencies were significantly decreased in 
Phase 2 acquisition when compared to Phase 1 (this result is also demonstrated in the 
graphs in Figure 6).    For Phase 2 acquisition, a one-way ANOVA was also conducted to 
view possible differences in trial latencies across the four drug treatment groups, N/N, 
N/S, S/N, or S/S.  The independent variable was the drug treatment group and the 
dependent variables were the trial latencies.  Effects of group for days 1 through 5 were 
not significant, indicating no significant differences between groups in the Phase 2 
acquisition trials.   
 Similar to the test trial analyses conducted in the single-phase cohort and Phase 1, 
a one-way ANOVA was conducted for test trial totals, and a separate ANOVA was 
conducted for test trial averages.  The independent variable was condition (rats that 
received either nicotine or saline in Phase 2), and the dependent variables were trial 
latencies.  The effect of condition on trial totals was significant, F(1, 29) = 9.16, p = .005, 
demonstrating that the nicotine treated adult rats had lower overall trial latencies 
compared to saline treated rats.  A significant effect of condition was also seen in trial 
averages, indicating lower trial latency averages in nicotine rats than in saline rats, F(1, 
29) = 9.16, p = .005 (see Figure 7 for a graph of Phase 2 test trial averages).  This shows 
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that the nicotine rats demonstrated increased learning of the task when compared to saline 
rats. 
Additionally, five one-way ANOVAs were conducted for each test trial in Phase 
2, with condition (nicotine or saline) as the independent variable and trial latencies as the 
dependent variable.  Significant effects of condition were found for trial 1, which had the 
same start location as the acquisition trials, F(1, 29) = 6.19, p = .019, trial 4, F(1, 29) = 
6.59, p = .016, and for trial 2, F(1, 29) = 4.12, p = .05.  This indicates that in these testing 
trials, the nicotine had a positive effect on the cognition of the older rats.  The effects in 
trials 3 and 5 were not significant.  These results, coupled with the results from the test 
trial totals and test trial averages, demonstrate that nicotine administration led to lower 
trial latencies in adult rats.   
A one-way ANOVA and LSD follow-up tests were then conducted to view 
differences between the four drug treatment groups, N/N, N/S, S/N, and S/S, in the Phase 
2 test trials.  The independent variables were the four groups with varying drug 
conditions, and the dependent variables were the trial latencies.  Trial totals for each 
group were calculated, and these scores were used in the ANOVA.  A significant effect 
of group was found for trial totals, F(3, 27) = 3.03, p = .047.  Least Square Difference 
(LSD) post-hoc tests conducted at a significance level of p < .05 confirmed that groups 
receiving nicotine responded more quickly in the MWM due to decreased trial latencies.  
LSD tests indicated that for trial totals, the N/N group was significantly faster than the 
N/S group (mean difference = 8.57) and the S/N group was significantly faster than the 
N/S group (mean difference = 9.31).   
Five one-way ANOVAs were conducted using the four groups as the independent 
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variables and the test trial latencies as the dependent variables, in order to view 
differences between groups in individual trials.  The effects of the groups in individual 
trials 1 through 5 were not significant.  However, LSD tests indicated a significant 
difference between the N/N group and S/S group in Trial 1 (mean difference = .81) and 
Trial 4 (mean difference = 2.08), as shown in Figure 8.  Though the effects of these were 
not significant in the ANOVA, the significant post-hoc test provides more support for the 
result that nicotine rats in Phase 2 were faster than saline rats.  For a graph demonstrating 
the differences between the N/N, N/S, S/N, and S/S test trial averages, see Figure 9.  
A one-way ANOVA was conducted for Phase Differences, which was the 
difference in latencies for the four groups (N/N, N/S, S/N, S/S) between Phase 1 and 
Phase 2.  A near-significant effect of condition was found, F(3, 27) = 2.93, p = .051, and 
no significant effect was seen for age alone.  This indicates an effect of the nicotine as the 
rats aged, however the lack of a significant result for age alone suggests that due to the 
previous training, there was no significant difference between test trial latencies in Phase 
2 versus Phase 1.  LSD post-hoc tests indicated a significant difference between the S/N 
and N/S groups, showing that the rats receiving saline in Phase 1 and nicotine in Phase 2 
(S/N) had significantly lower trial latencies than rats receiving nicotine in Phase 1 and 
saline in Phase 2 (N/S) (mean difference = 16.36).   
c-Fos Analysis  
 Separate one-way ANOVAs were conducted for Phase 2 of the dual-phase cohort 
and the single-phase cohort to analyze c-Fos expression in the dentate gyrus of the 
hippocampus.  Here, the independent variables were the drug conditions and brain 
sections, while the dependent variable was c-Fos content.   
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 For Phase 2, three one-way ANOVAs were conducted across condition (nicotine 
or saline) on c-Fos expression separately for each section of the hippocampus.  The three 
sections of interest were the rostral, middle, and caudal portions of the dentate gyrus.  A 
significant effect of condition was seen in the caudal section, F(1, 26) = 10.43, p = .003.  
Means indicate that the rats receiving saline in Phase 2 (M = 14.47) had higher c-Fos 
content in this section than did the rats receiving nicotine in Phase 2 (M = 9.23).  Effects 
for the rostral and middle sections were not significant, indicating the largest c-Fos 
difference occurred in the caudal hippocampus section.  See Figures 10, 11, and 12 for 
examples of rostral, middle, and caudal sections of the dentate gyrus for both saline and 
nicotine rats.  A one-way ANOVA conducted for the single-phase cohort revealed no 
significant effect of condition across nicotine and saline rats in any brain section, 
indicating that the nicotine did not have an effect on c-Fos content in the adolescent rats.   
 Three one-way ANOVAs and LSD post hoc tests at significance level p < .05 
were also conducted in Phase 2 to view differences between the N/N, N/S, S/N, and S/S 
groups in the three hippocampus sections.  Here, the independent variables were the four 
groups, and the dependent variable was the c-Fos content.  Again, the effect of group for 
the caudal section was significant, F(3, 24) = 4.14, p = .017, indicating significantly 
higher c-Fos expression in the saline rats.  LSD post-hoc tests indicated that S/S rats had 
significantly more c-Fos than N/N rats (mean difference = 6.08), and than S/N rats (mean 
difference = 7.00).  No significant effects of group were seen for the rostral and middle 
sections.   
 To view differences relating to age between the Phase 2 rats and the single-phase 
cohort, three 2 (age) x 2 (condition) ANOVAs were conducted for the three hippocampus 
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sections of interest.  Phase 2 rats were considered adults and single-phase cohort rats 
were adolescents, and they compared by condition (nicotine or saline).  Again, a 
significant effect of condition was seen in the caudal section of the hippocampus, F(1, 
37) = 8.22, p = .007, indicating the saline rats showed more c-Fos expression than the 
nicotine rats.  Significant effects for age were seen in the rostral section, F(1, 37) = 5.34, 
p = .027, and the caudal section, F(1, 37) = 5.78, p = .021, indicating that adolescent rats 
showed less c-Fos expression than adult rats.  The effect of age in the middle section 
indicated a trend toward significance, F(1, 37) = 3.52, p = .069.   
BrdU Analysis 
No BrdU expression was demonstrated in the dentate gyrus of the hippocampus in 
the rostral, middle, and caudal sections examined for the single-phase and dual-phase 
cohorts.   
Discussion 
 The hypothesis that rats receiving nicotine would be significantly improved in the 
test trials of the Morris water maze task when compared to rats receiving saline was 
partially supported:  The adult rats demonstrated a clear improvement in the task after 
nicotine exposure, while the adolescent rats did not demonstrate such improvement.  As 
expected, in Phase 2 testing the N/N rats were significantly improved at the task when 
compared to the three other groups, and the S/N rats were improved compared to the S/S 
and N/S groups that received saline in Phase 2.  The hypothesis that previous training in 
the Morris water maze would lead to lower trial latencies overall in Phase 2 of acquisition 
was supported, as all rats (regardless of drug condition) demonstrated much faster 
reaction times than they did in Phase 1.  However, the hypothesis that nicotine rats in 
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Phase 2 of acquisition would re-acquire the task faster than the saline rats was not 
supported, indicating that the nicotine did not have an effect on the re-acquisition of the 
task from the same start location. 
 The hypothesis regarding c-Fos in the dentate gyrus of the hippocampus was not 
supported, as we expected to see an increase in c-Fos in the nicotine rats.  There was, 
however, a significant increase in c-Fos in the dentate gyrus of the rats that received 
saline in Phase 2, as the S/S group had a much higher amount of c-Fos than the N/N and 
S/N groups.  Additionally, it was found that adult rats demonstrated more c-Fos 
expression in the hippocampus than adolescents from the single-phase cohort.  The 
hypothesis that there would be an increase in BrdU in the dentate gyrus of the nicotine 
rats was not supported, as we were not able to obtain any BrdU expression in our tissue.  
This could have been due to a number of methodological factors, which will be expanded 
upon later.   
Behavioral Effects of Nicotine 
In adolescent rats, contrary to our original hypothesis, there were no significant 
differences between the nicotine and saline rats.  These rats were approximately two 
months old, and still at an early stage of development.  It is possible that the lack of a 
significant difference in the acquisition and test trials for the adolescent rats (in both the 
single-phase cohort and Phase 1 of the dual-phase cohort) is due to the fact that a nicotine 
dose of 0.2 mg/kg/day is not enough to demonstrate such an effect in rats of this age.  It 
has already been demonstrated that adolescent rats metabolize drugs faster than adult rats, 
so it is possible that in order to see a change in trial latencies, adolescent rats would need 
to be administered a higher dose of nicotine (French et al., 2006).  This conclusion 
  Effects of Nicotine 50
coincides with a previous study that gave adolescent and aged rats a high nicotine dose of 
0.5 mg/kg/day, but demonstrated an improvement in the working memory of the 
adolescent rats only (Levin & Torry, 1996).  This provides evidence for a possible dosing 
threshold in both adolescents and adult rats.   
In Phase 2 of testing, when the rats in the dual-phase cohort were approximately 6 
months old and thus considered adults, complete support of our hypothesis was 
demonstrated.  The results from the test trials for this phase, in which rats were to find the 
hidden platform from varying start locations, demonstrated a clear decrease in trial 
latencies in the nicotine rats as compared to the saline rats.  This follows from studies that 
have demonstrated nicotine as having a pronounced effect on aged rats (French et al., 
2006; Socci et al., 1995).  Additionally, previous studies have demonstrated the 
importance of allowing a few days for the drug to take effect before starting acquisition 
trials (Bernal et al., 1999).  Because the rats in this study were given a week prior to 
acquisition to acclimate to the drug, it can be concluded that the effects of the nicotine in 
the Morris water maze in Phase 2 of testing were due to the nicotine itself and not some 
other factor.  It can also be concluded that the improvement in the Morris water maze 
task among adult rats receiving nicotine was not due to an increase in locomotion as a 
result of the nicotine, as the results demonstrate that nicotine did not have an effect on the 
activity levels of the rats.  This provides more evidence that the nicotine served to 
increase the cognition of the rats, and not merely to increase their locomotion. 
Our study is unique in that the rats in the dual-phase cohort were given varying 
drug schedules that allowed for four separate groups to be examined—this allows us to 
draw conclusions regarding the level of impact the nicotine has on the rats’ ability to 
  Effects of Nicotine 51
learn the Morris water maze task.  In Phase 2, our hypothesis was supported because we 
found that the N/N rats had significantly lower latencies in the test trials than the N/S rats 
and the S/S rats.  This provides evidence that learning in the Morris water maze was 
state-dependent on the nicotine—when rats received nicotine in Phase 1 and then nicotine 
again in Phase 2, they performed very well in the test trials in Phase 2.  When rats 
received nicotine in Phase 1 and saline in Phase 2, they demonstrated impairment when 
compared to all other rats (including the S/S group).  This suggests that when rats are 
deprived of nicotine and then faced with a task they learned while under the influence of 
nicotine, the absence of nicotine leads them to perform worse on the task than they would 
have if they had never received nicotine in the first place.  In Phase 2 of this study, 
however, the rats were faced with the same exact task under identical conditions.  It is 
possible that if faced with a slightly different task, or the same task in a different 
environment, the deficits would not be as pronounced.  Thus, the extent to which learning 
is state-dependent on nicotine is an area that lends itself to further study.   
 These results also demonstrate the importance of previous training in conjunction 
with the drug treatment, as the re-acquisition of the task in Phase 2 demonstrated lower 
latencies overall than did the acquisition in Phase 1.  Clearly the previous training helped 
the animals learn the task, most likely due to Long Term Potentiation (LTP) in the 
hippocampus.  Because the training led to an increase in neuronal firing and expression, 
the rats were able to perform better during the second phase of acquisition.  This follows 
from previous research that highlights early training as an indicator of long-term 
memory—because the rats remembered the task from the previous acquisition phase, they 
were able to re-acquire it much more quickly in Phase 2 (Hansalik et al., 2006).   
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Because the nicotine did not produce a significant difference in acquisition trials 
in Phase 2, it can also be concluded that the previous training in the maze from that start 
location is what allowed the rats to recall the task much more quickly than they did in 
Phase 1.  Additionally, the test trial latencies in Phase 2 did not differ overall from test 
trial latencies in Phase 1—thus, the main difference in latencies from one phase to the 
next was seen in the acquisition trials.  The real difference between nicotine and saline 
rats was seen in the Phase 2 test trials, in which the rats had to remember the task relying 
only on spatial cues.  In this instance, it is clear that the nicotine improved the spatial 
learning and memory retention in the rats.      
Neuronal Effects of Nicotine 
Initially, we hypothesized that there would be an increase in c-Fos expression in 
the adult rats in Phase 2 as a result of the nicotine expression.  Though this hypothesis 
was not supported, a significant result in the opposite direction was found.  The saline 
rats in Phase 2 demonstrated an increase in c-Fos in the dentate gyrus of the hippocampus 
when compared to nicotine rats.  Though this did not follow with our hypothesis 
regarding c-Fos as an indicator of neuronal change, it follows from previous research 
investigating c-Fos as an indicator of stress (Kovacs, 1998).  Previous research 
demonstrating an increase in c-Fos as a result of nicotine exposure has shown that higher 
doses (of up to 2 mg/kg) of nicotine lead to this expression (McCormick & Ibrahim, 
2007; Ren & Sagar, 1992).  Because the dose used in the present study was quite low (0.2 
mg/kg), it is possible that this was not enough nicotine to produce a c-Fos increase in the 
nicotine rats.  That being said, the increase in c-Fos in saline rats could instead be due to 
the increased amount of stress the saline rats were under.  Because the results show that 
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saline rats demonstrated significantly higher latencies in the test trials of the MWM task, 
it is possible that being in the maze for a longer period of time led to more stress in these 
rats when compared to the nicotine rats that were in the maze for much shorter periods of 
time.  This follows from studies examining the effects of swim stress on rats—rats forced 
to swim (usually for 15 minutes) with no escape platform show high stress levels as 
indicated by increased c-Fos expression in the brain (Lino-de-Oliveira et al., 2006). 
Though it seems this will often be a confound in an experiment like this, it would 
be possible to use a different Morris water maze method that would eliminate the 
possibility of increased stress in the rats with higher trial latencies.  In this experiment, 
the platform was present at all times during the test trials.  A future experiment could 
employ the use of a camera suspended over the maze during test trials—the platform 
would be removed, and the amount of time the rats spend in each quadrant would be 
assessed instead.  The amount of time spent in the quadrant that contained the platform 
during acquisition would be the measure of spatial learning.  This way, all rats would be 
in the maze for the same amount of time (generally 60 seconds), and increased stress as a 
result of higher swimming times would not potentially skew the c-Fos results.   
Though we expected to see an increase in cell proliferation in the dentate gyrus of 
the hippocampus as evidenced by BrdU, no such staining was obtained.  Due to a number 
of studies demonstrating an increase in neurogenesis in the hippocampus as evidenced by 
BrdU expression after nicotine administration and spatial learning, the lack of BrdU 
staining is most likely because of a problem with our procedure (Dalla et al., 2007; 
Dobrossy et al., 2003).  It is possible that the number of injections was not enough to lead 
to significant BrdU staining in the hippocampus.  Previous studies employing the use of 
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BrdU generally use three or more injections of 50 mg/kg BrdU, or they use one or two 
injections of an extremely high concentration of BrdU (Dalla et al., 2007; He & Crews, 
2007; Scerri et al., 2006).  In this study, we only injected the rats twice with a 
concentration of 50 mg/kg BrdU, and it is possible that in order for the nicotine or 
training to have an impact on BrdU expression we would have needed more injections.   
In addition to administering more BrdU injections, it would be beneficial in the 
future to modify the injection schedule so the timing coincides with the time when the 
most learning takes place.  A previous study divided the learning process in the Morris 
water maze into an early phase, in which most of the learning occurs, and a late phase, in 
which the latencies decrease and level off (Dobrossy et al., 2003).  It was found in the 
study that the early phase of learning did not produce significant cell proliferation 
potentially due to increased stress of a new task, but that the late phase of learning did 
demonstrate increased cell proliferation as evidenced by BrdU (Dobrossy et al., 2003).  
However, the study employed fewer acquisition trials per day, and they only looked at 
acquisition (what they termed “learning”) trials.  The timing of our injections was right 
before the last day of acquisition and before the first day of testing—it is possible that 
because at this point the rats had already significantly learned the task, there were not 
enough newly-formed cells to demonstrate BrdU incorporation in the hippocampus.  It 
can also be argued that the later acquisition trials in our study were less hippocampal-
dependent because the rats had already been exposed to a number of trials from the same 
start location.  If this is the case, it makes sense that there was no BrdU expression in the 
hippocampus after these trials.  Instead, administering injections during the first 
acquisition days in which the bulk of the learning occurs would most likely lead to an 
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increase in BrdU expression.    
Due to our knowledge of the effects of nicotine at the neural level, it can be 
concluded that despite the lack of c-Fos and BrdU expression in the nicotine rats, the 
nicotine still had an effect on the nAChRs in the rats’ brains.  The hippocampus is known 
to be highly involved in memory and learning due to LTP, which is an increase in 
synaptic effectiveness.  Because the behavioral data demonstrated that the adult rats 
treated with nicotine were significantly improved in the Phase 2 test trials, we can reach 
the conclusion that the nicotine was binding to nAChRs and stimulating the release of 
neurotransmitters in the brain.  This led to an increase in neuronal firing, as indicated by 
the enhancement in their cognition as related to the Morris water maze task.   
The results of this study follow from previous studies investigating the effects 
nicotine has on the hippocampus.  It has been shown that nicotine facilitates synaptic 
activity and can increase LTP in the hippocampus via tasks involving memory and 
learning (Rezvani & Levin, 2001).  Nicotine’s positive effect on LTP has also been 
supported by studies investigating nicotine as a neuroprotective agent in rats that have 
been exposed to significant stressors (Aleisa et al., 2006).  In the case of Alesia and 
colleagues (2006), nicotine was shown to normalize LTP and counteract working 
memory impairments that were induced by stress.  Nicotine has also been shown to 
attenuate working memory deficits as induced by certain drugs, again providing evidence 
that nicotine is neuroprotective and plays a significant role in LTP in the hippocampus 
(Levin, Bettegowda et al., 1998). 
While there is significant evidence that nicotine leads to increased neuronal firing 
and LTP in the hippocampus as a result of tasks involving memory and learning, it is 
  Effects of Nicotine 56
possible that the site of neuronal change could be elsewhere in the brain, or in addition to 
these hippocampal effects.  Studies have shown that nAChRs are also present in other 
brain areas, such as the amygdala, the prefrontal cortex, the thalamus, and the motor 
cortex (Levin, McClernon et al., 2006; Mansvelder et al., 2006).  It would be beneficial 
to investigate these brain areas with respect to nicotine exposure and working memory 
tasks, as this would provide a more complete view of the neural mechanisms of nicotine.      
Limitations 
 The limitations of this study mostly involved the newness of the procedure.  The 
osmotic mini pumps had never been used in this laboratory before, and due to some 
complications in the first round of surgeries a few rats lost their pumps.  This was most 
likely due to poor placement of the pumps, as the first batch had the releasing end of the 
pump facing the wound.  The excessive scratching that led to the loss of the pumps could 
have been due to the nicotine aggravating the wounds before they healed.  After the first 
round of surgeries all other surgeries were completed without incident, providing further 
evidence that the pump placement was the reason for the excessive scratching and 
subsequent pump loss.   
The use of BrdU was another limitation in this study.  It did not immediately go 
into solution, so based on the findings of previous studies we heated the BrdU 
significantly in order to help it dissolve (Hume & Keat, 1990).  We later found, however, 
that heating BrdU might actually decrease the likelihood that it will incorporate into new 
neurons.  Despite this, the previous literature that used the heating technique did still see 
BrdU expression—thus, it was most likely a problem with the timing of our injections 
that led to the lack of expression (Hume & Keat, 1990).  The results from the present 
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study suggest that the ideal time to inject BrdU is when learning is most evident, which 
would have been during days 1 and 2 of the acquisition trials.   
 Another potential limitation in this study could have been in the use of the Morris 
water maze.  There are a few different ways the Morris water maze can be used to 
demonstrate spatial learning, and the procedure used in this study may be unusual 
compared to other, more widely used procedures.  Because the rats were to be exposed to 
the maze four months after Phase 1 of testing, we wanted to ensure that the rats learned 
the task as well as possible during Phase 1.  For this reason, we chose to have five days of 
acquisition, with five trials from the same start location each day.  As the results indicate, 
the rats learned the spatial cues by the end of acquisition trials in both Phase 1 and 2.  It 
can be argued that by the end of the acquisition trials the task was no longer 
hippocampal-dependent because the start location remained the same; however the good 
performance of the rats in the test trials indicates that the hippocampus was still highly 
involved in the task.   
There have been previous studies using the Morris water maze as both a 
hippocampal-dependent and independent task.  It has been found that when the task 
involves spatial learning, such as in a traditional Morris water maze study in which rats 
must locate a hidden platform, it is dependent upon the hippocampus (Teather, Packard, 
Smith, Ellis-Behnke, & Bazan, 2005).  This has been evidenced by an increase in c-Fos 
in this brain area after such a task (Teather et al., 2005).  When a task is due to a 
stimulus-response “habit,” such as in a Morris water maze task in which the platform is 
visible, the task can be completed independent of the hippocampus, with more reliance 
on the dorsal striatum.  In the case of habitual learning, the increase in c-Fos is seen in the 
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dorsal striatum, and not the hippocampus (Teather et al., 2005).  Based on the findings of 
this study, it is possible that the later acquisition trials in the present study were more 
habitual, and that they relied on the dorsal striatum more than the hippocampus.  Yet 
these findings still provide support for the test trials as being hippocampal-dependent 
because the rats had to find the hidden platform from unfamiliar start locations around the 
maze.   
 Many Morris water maze studies also employ the use of a video camera in order 
to assess the amount of time rats spend in each quadrant when the platform is removed 
(Bernal et al., 1999; Socci et al., 1995).  Because this kind of technology was not 
available to our laboratory at the time of Phase 1 acquisition and testing, we chose to 
keep the platform in the maze for all parts of the experiment.  Therefore, it was necessary 
to have all acquisition trials begin at the same start location, and to test the learning of the 
task using 5 different start locations around the maze.  Although this is a more traditional 
method of assessing Morris water maze spatial learning, it still yielded significant results 
and demonstrated that, after 5 days of acquisition and 1 test day at varying start locations, 
rats learned the task as evidenced by a significant decrease in trial latencies (Morris, 
1984).   
 This study may have also been limited by low statistical power.  Though it began 
with 50 subjects and an even number of nicotine and saline rats in each group, 
complications with the surgeries and pumps caused these numbers to decrease, and 
ultimately the data from four subjects were lost before the close of the experiment.  
Though the results from the test trials were significant, it is possible that any differences 
in the adolescent rats in Phase 1 were too subtle to be demonstrated by the small number 
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of rats used in each group.  Additionally, the complicated nature of the study design led 
us to perform many statistical analyses, which could have contributed to the possibility of 
Type I error.  Despite this, the conclusions made were based largely on the results of tests 
using trial totals and averages, and the separate ANOVAs conducted were simply to view 
potential differences within the days of acquisition, and within the individual test trials.  
It may be necessary in the future, however, to alter the experimental design to allow for 
fewer statistical analyses to avoid this potential problem.   
Implications 
 The results of this study lead to a number of implications that can be translated to 
human studies of nicotine’s cognitive-enhancing properties.  The finding most relevant to 
human research is that nicotine did enhance the cognition of the adult rats.  This 
conclusion provides continuing support the use of nicotine as a therapeutic alternative for 
people suffering from diseases affecting cognition, including Alzheimer’s disease.  It also 
paves the way for future studies in this area that will give us even more information about 
the cognitive enhancing properties of nicotine, and how it can be best utilized for 
treatment of such disorders. 
 The fact that we tested adult rats that were 6 months old as opposed to “aged” rats 
that were up to 24 months old could be a potential limitation of this study because it 
makes it difficult to compare to previous literature.  Most studies examining the 
differences between young and aged rats use aged rats because it is easier to relate to 
human studies of elderly people, particularly ones with age-associated memory 
impairments.  The fact that we used adult rats, however, is also beneficial because of the 
lack of research done on rats of this age group—we were able to demonstrate that adult 
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rats benefited from a small amount of nicotine, which provides important results 
regarding a potential dosing threshold between adolescent and adult rats.  Previous 
studies have only been able to demonstrate that adolescent rats need a higher dose than 
aged rats—the current study is able to narrow that age gap, and it suggests that there is a 
point between the age of 2 months and 6 months where the dose of nicotine can be 
decreased dramatically.   
This translates to human studies involving nicotine by suggesting that if adults are 
facing a disease affecting their cognition, they do not need a dose as high as an 
adolescent might need in order to delay the onset of this disease.  This could dramatically 
decrease the potential dangers of employing the use of nicotine patches in adult patients, 
because they would not be exposed to extremely high doses of nicotine that could lead to 
adverse side effects or increased likelihood of addiction.   Instead, future studies of 
nicotine’s use in adults facing cognitive impairments could begin using a relatively low 
dose of nicotine—if that does not produce the desired effects, then a higher dose might be 
tested.  But the fact that the adult rats in this study benefited from the same low dose that 
has been shown to improve cognition in aged rats provides evidence that adult humans 
may also benefit from the same dose as the elderly (Socci et al., 1995).  Human studies of 
nicotine employing the use of nicotine patches delivering 0.9 mg/kg per hour (considered 
a moderate dose) to patients in their late 70’s have demonstrated a clear improvement on 
tasks of cognition (Wilson et al., 1995).  Based on the results of the current study, it 
would most likely not be necessary to give an adult a higher dose than that in order to 
improve cognition. 
The results regarding the dose in this study are also important in demonstrating 
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that cigarette smoking is not a safe therapy to use for people with diseases affecting 
cognition.  Though it has been hypothesized that many patients with schizophrenia and 
ADHD self-medicate with cigarettes to obtain nicotine, the results of this study imply that 
this practice can actually have adverse effects upon the patients due to the very high dose 
of nicotine and the other harmful ingredients in cigarettes (Levin, McClernon et al., 2006; 
Winger et al., 2004).  Cigarette smoking can actually impair cognition because the non-
nicotine ingredients can restrict blood flow to the brain and lead to cell death.  Also, the 
very high amount of nicotine in cigarettes can actually decrease cognition due to receptor 
desensitization (Winger et al., 2004).  Thus, nicotine should really be administered by 
itself and in a low dose to decrease the potential negative side effects of the drug. 
It can also be concluded from the current study that the performance of the adult 
rats in the Morris water maze was state-dependent on the nicotine.  This means that after 
being exposed to nicotine in conjunction with the spatial learning task, it was necessary 
to provide nicotine to the rats in any future exposures to the same task.  This is why the 
group that received nicotine in Phase 1 was impaired in Phase 2 when they received 
saline—their learning of the task was dependent on the nicotine, and thus their trial 
latencies without it were much higher than rats in all other groups.  It is possible, 
however, that the detriment in the N/S group might not have been evident if they were 
exposed to a different task, or the same task under new circumstances.  In the current 
study, it is not possible to separate the state-dependent effect from the potential long-term 
benefits because we used the same spatial learning task to assess memory retention in 
both phases.   
Despite the current data regarding the state-dependent effects of nicotine, it is not 
  Effects of Nicotine 62
likely that nicotine cessation would produce such profound deficits in humans after 
learning a task.  In a study examining the potential cognitive deficits due to withdrawal 
from the nicotine in cigarettes, impairments on tasks of cognition were seen a few hours 
following cessation of the drug (Hatsukami et al., 1989).  However, it was mentioned that 
other studies using similar methods demonstrated that test scores on tasks of cognition 
after quitting were higher than scores obtained when the same participants were engaged 
in cigarette smoking (Hatsukami et al., 1989).  This suggests that the decline in the study 
done by Hatsukami and colleagues (1989) may not have been wholly due to the nicotine 
cessation, but also due in part to lasting negative effects of the combination of ingredients 
in cigarettes.  Additionally, the study did not test their participants beyond 24 hours after 
quitting—this would be crucial for conclusions that nicotine cessation produces long-
term cognitive deficits.  Because this was not done, it is not possible to make this kind of 
assertion.   
In order to further examine whether cognitive tasks are state-dependent on 
nicotine in humans, it would be necessary to perform follow-ups to the studies on 
nicotine’s effect on human cognition.  There have been a number of studies 
demonstrating that a chronic (or even acute) dose of nicotine improves memory and 
learning in Alzheimer’s patients, however it would be beneficial to re-examine these 
patients after a significant period of time with the same tasks to see if the absence of 
nicotine has a negative effect on their ability to perform the task (Jones et al., 1992; 
Sahakian et al., 1989; Wilson et al., 1995).  This would provide more concrete evidence 
for the state-dependent effects of nicotine in humans. 
The conclusion from the current study that c-Fos was increased in the 
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hippocampus potentially due to the elevated stress levels of the saline rats has interesting 
implications for human studies.  It suggests that humans who are facing the beginning 
stages of cognitive decline could be under significantly more stress than people not 
undergoing the same decline.  Though more research would need to be done in this area, 
it can be hypothesized that if humans are given nicotine to enhance their cognition at 
these beginning stages, they may be under much less stress because they would not have 
the same level of difficulty performing everyday tasks.  Additionally, this provides some 
evidence that perhaps nicotine has anxiolytic effects.  This is a result that would benefit 
from further study, because it provides more support for the development of a therapeutic 
treatment for such diseases that enhances cognition and delays the onset of marked 
cognitive decline.    
Future Studies 
 Because this is a preliminary study, it lends itself to replication on a larger scale.  
Increasing the number of subjects in each group would be extremely beneficial, as the 
increase in power would potentially demonstrate subtle changes between groups, 
particularly in the adolescent rats.  There were many trends toward significance, and it is 
assumed that with more subjects, there would be more clear indications of significance.  
Replicating this study would also be beneficial as many of the problems encountered 
would be anticipated and resolved before they occurred.  It is now known how to 
properly perform the surgeries, so this would not be a complication, and the 
administration of BrdU would be handled differently.  More injections of BrdU would be 
administered, and the timing of these injections would be altered so that the rats would be 
injected during the first two acquisition days.  These days were when the bulk of the 
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learning occurred, so it is most likely that injections during these two days would lead to 
an increase in BrdU expression in the hippocampus.   
 This study also paves the way for further research in this area.  We demonstrated 
that a nicotine dose of 0.2 mg/kg showed a significant decrease in the trial latencies of 
adult rats in the Morris water maze, but this dose did not demonstrate a decrease in 
latencies in adolescents.  In the future, this experiment could be replicated by giving a 
group of adolescent and adult rats a higher dose of nicotine (for example, 0.4 mg/kg), in 
order to determine whether this dose improves the performance of the adolescents, and 
whether it impairs the performance of the adults.   
 Because the results regarding c-Fos expression in the dentate gyrus of the 
hippocampus were unexpected, further research regarding nicotine’s effect on c-Fos 
expression in the rat brain would be beneficial to our understanding of this relationship.  
In order to demonstrate whether the increased c-Fos expression was due to the stress of 
having higher trial latencies, it would first be useful to look at c-Fos as a result of Morris 
water maze training alone—then the results could be separated into rats with longer 
latencies and rats with shorter latencies, to see if the rats that spent more time in the maze 
had more c-Fos expression.  It would also be beneficial to examine c-Fos expression in 
the rat hippocampus as a result of nicotine when stress is not a factor.  This would simply 
involve administering nicotine for a certain length of time and then examining c-Fos 
expression in the hippocampus after that time.  If there is c-Fos present in the nicotine 
rats, it can be concluded that nicotine increases c-Fos expression when stress is not a 
factor.   
 Because the present study examined the hippocampus only, it would certainly be 
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beneficial to examine other brain areas that are linked both with memory and learning, 
and also with stress.  This would be useful to provide conclusions regarding the effects of 
the nicotine at the neural level.  Because nicotine can lead to increased attention in 
humans, it has been proposed that nicotine may also have an effect on the prefrontal, 
parietal, and occipital cortex, as well as the amygdala, and the hippocampus (Mansvelder 
et al., 2006).  Additionally, the thalamus and the motor cortex have also been shown to 
demonstrate a high number of nAChRs, which could also have implications regarding 
nicotine’s effect on the human as well as the rat brain.  Replicating this study and 
examining c-Fos or BrdU expression in some of these brain areas could be extremely 
beneficial for this field of research, as the largest amount of work has been done with the 
hippocampus.  Paying closer attention to the brain areas about which less is known 
regarding nicotine’s effects could lead to some important conclusions that could be 
carried over to human studies of nicotine.  Examining nicotine’s effect on the motor 
cortex could be particularly interesting when testing rats in motor tasks like the Morris 
water maze, because if nicotine stimulates neuronal growth in this brain area it could 
have a significant impact on the ease with which the rats acquire the task. 
Conclusions 
 The current study provides support for the use of nicotine as a therapeutic agent in 
diseases affecting cognition.  Because of nicotine’s direct stimulation of nAChRs in the 
human brain, it would be a more effective alternative to the current treatments available 
for diseases like Alzheimer’s, which provide minimal symptom relief.  Though a 
considerable amount of information is known about nicotine’s effects on the 
hippocampus, it is important that future studies examine nicotine’s effects on different 
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brain areas in order to provide a more comprehensive view of its neural mechanisms.  
Once this knowledge is attained, it will hopefully lead the use of nicotine as a therapeutic 
drug—this has the potential to dramatically increase the quality of life for people 
suffering from diseases affecting their cognition. 
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Table 1 
 
 _______________________________________________________________________ 
 
Drug Treatment Groups 
 _______________________________________________________________________ 
 
Group  Phase 1  Phase 2  Number of Subjects 
 
N/N  Nicotine  Nicotine   7 
 
N/S  Nicotine  Saline    7 
 
S/N  Saline   Nicotine   9 
 
S/S  Saline   Saline    8 
 _______________________________________________________________________ 
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Table 2 
 _______________________________________________________________________ 
Experiment Schedule 
 _______________________________________________________________________ 
Experimental Day 1 2 3 4 5 6 7 8 
Phase 1  A A A A A - - T 
Phase 2   
(and single-phase A A A A - A T 
cohort) 
 _______________________________________________________________________ 
Note.  A = Acquisition day, T = Test day, dash (-) = no trials 
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Figure Caption 
Figure 1.  Morris water maze start locations and platform placement. 
 
Figure 2.  Mean trial latencies for single-phase cohort acquisition. 
Figure 3.  Mean trial latencies for single-phase cohort test trials. 
Figure 4.  Mean trial latencies for Phase 1 acquisition. 
Figure 5.  Mean trial latencies for Phase 1 test trials. 
Figure 6.  Mean trial latencies for Phase 2 acquisition compared to mean trial latencies 
for Phase 1 acquisition. 
Figure 7.  Mean trial latencies for nicotine and saline rats in Phase 2 test trials. 
Figure 8.  Mean trial latencies for N/N and S/S rats in Phase 2 test trials. 
Figure 9.  Mean trial latencies for N/N, N/S, S/N, and S/S in Phase 2 test trials. 
Figure 10.  Photograph of c-Fos expression in saline and nicotine rats in the rostral 
section of the dentate gyrus (arrows point to examples of c-Fos particles).   
Figure 11.  Photograph of c-Fos expression in saline and nicotine rats in the middle 
section of the dentate gyrus.   
Figure 12.  Photograph of c-Fos expression in saline and nicotine rats in the caudal 
section of the dentate gyrus.   
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Figure 1. 
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Figure 2. 
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Figure 3.  
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Figure 4.  
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Figure 5. 
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Figure 6.   
    Phase 1 Acquisition Trials 
     Phase 2 Acquisition Trials 
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Figure 7. 
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Figure 8. 
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Figure 9. 
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Figure 10. 
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Figure 11. 
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Figure 12. 
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